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BACKGROUND:	 Pancreatic	 ductal	 adenocarcinoma	 (PDAC)	 is	 usually	 a	 systemic	
disease	 and	 so	 requires	 chemotherapy	 even	 when	 surgical	 resection	 is	 possible.	
Current	agents	such	as	gemcitabine	are	only	effective	in	a	minority	of	patients	and	
chemoresistance	 is	 an	 important	 issue	 faced	 in	 pancreatic	 cancer.	 	 There	 is	 an	
urgent	 need	 for	more	 effective	 therapies;	 Novel	 agents	may	 offer	 an	 avenue	 for	
this.	 The	 CDK	 family	 of	 protein	 kinases	 are	 pivotal	 in	 cell	 cycle	 regulation	 that	 is	
often	 deranged	 in	 cancer.	 HSP90	 is	 a	molecular	 chaperone	 affecting	multiple	 key	
cellular	signaling	pathways	of	importance	in	pancreatic	cancer.	
OBJECTIVES:	 To	 determine	 the	 efficacy	 of	 AT7519,	 a	 novel	 CDK	 inhibitor,	 and	
AT13387,	a	novel	HSP90	 inhibitor	 in	pancreatic	cancer	models	 in	vivo	and	 in	vitro	
both	as	single	agents	and	in	combination	with	gemcitabine.	
METHODS:	 Cell	 proliferation	 was	 measured	 using	 the	 EZ4U	 assay.	 	 Cell	 cycle	





RESULTS:	 AT7519	 inhibited	 proliferation	 in	 cell	 lines	 including	 a	 gemcitabine	
resistant	 line	 (SUIT-2	GR)	with	 IC50	 values	 ranging	 5-2000nM.	 	 Cell	 cycle	 analysis	
showed	actions	 in	 line	with	CDK	 inhibition.	 	At	24	hours	 induction	of	 caspase	3/7	
was	significantly	 increased	in	AT7519	treated	cells	compared	with	those	in	control	
media	(p=0.01).		Phosphorylation	of	client	proteins	were	inhibited.		Isobolar	analysis	
of	 AT7519	 combined	with	 gemcitabine	 suggested	 an	 additive	 effect.	 AT7519	was	
tolerated	 as	 a	 single	 agent	 and	 in	 combination	 with	 gemcitabine	 in	 a	 xenograft	
model	and	resulted	in	slowed	tumour	growth	compared	to	control	(p	=	0.0446).			
AT13387	 inhibited	 proliferation	 of	 all	 cell-lines	 with	 IC50	 values	 of	 29nM-325nM	
including	 a	 cell	 line	with	 acquired	 gemcitabine	 resistance.	 	 AT13387	 treated	 cells	
accumulated	 in	G0/G1	and	G2/M	phases	of	 the	cell	 cycle	 (p<0.05).	Late	apoptosis	
was	seen	after	40	hours	post	treatment	with	At13387.		AT13387	treatment	resulted	
in	 down-regulation	 of	 HSP90	 client	 proteins	 and	 up-regulation	 of	 the	 HSP70	 co-
chaperone.		AT13387	was	tolerated	and	moderately	efficicacous	as	a	singe	agent	in	




AT13387	 showed	promising	effects	 in	 vitro	but	was	poorly	 tolerated	 in	an	 in	 vivo	
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10-25%	 in	 resected	 disease(Richter,	 Niedergethmann	 et	 al.	 2003;	 Cress,	 Yin	 et	 al.	
2006).		The	mortality	roughly	equates	to	the	incidence;	in	2012	in	the	UK	there	were	
8,888	new	cases	of	pancreatic	cancer	and	8,622	deaths(UK	2014).		Despite	advances	














females	 overall,	 though	 there	 is	 some	 geographical	 variation.	 	 For	 men	 the	 age-




Geographically	 the	 highest	 incidence	 for	 men	 is	 observed	 in	 Eastern	 Europe	 and	
North	 America,	 the	 lowest	 in	 southern/northern	 Africa	 and	 Southeast	 Asia.	 	 For	






due	 to	 a	 genetic	 predisposition	 associated	 with	 a	 range	 of	 syndromes	 and	






A	 number	 of	 large	 epidemiological	 studies	 have	 established	 an	 increased	 risk	 of	
cancer	with	a	positive	family	history(Fernandez,	La	Vecchia	et	al.	1994;	Klein,	Brune	
et	al.	2004;	McWilliams,	Rabe	et	al.	2005).	Most	of	this	elevated	risk	is	probably	due	
to	 multigenetic	 factors,	 but	 there	 is	 evidence	 for	 a	 rare	 autosomal	 dominant	
condition	 (Familial	 Pancreatic	 Cancer).	 	 Early	 studies	 demonstrated	 families	 with	
increased	incidence	but	the	onset	of	cancer	was	not	early	and	histology	and	survival	
similar	 to	 sporadic	 cases	 (Ehrenthal,	 Haeger	 et	 al.	 1987;	 Ghadirian,	 Boyle	 et	 al.	
1991).	 	 	 	From	case-control	and	cohort	studies	 it	 is	clear	that	having	a	single-close	
relative	 with	 pancreatic	 cancer	 doubles	 an	 individuals	 lifetime	 risk	 of	 developing	
PDAC(Amundadottir,	 Thorvaldsson	 et	 al.	 2004;	 Hassan,	 Bondy	 et	 al.	 2007).	
Epidemiological	 studies	 have	 also	 shown	 that	 patients	 with	 a	 family	 history	 of	
pancreatic	cancer	also	have	an	increased	risk	of	extra	pancreatic	malignancies,	but	
this	 is	 not	 necessarily	 true	 in	 the	 autosomal	 dominant	 syndrome.	 	 Wang	 et	 al	
demonstrated	 that	 relatives	 of	 patients	 with	 cases	 of	 pancreatic	 cancer	 have	 an	









In	 most	 individuals	 with	 a	 predisposition	 for	 cancer	 the	 gene	 involved	 remains	
unknown,	however	a	number	of	known	genetic	syndromes	show	associations	with	
increased	risk	of	pancreatic	cancer	summarised	in	table	1.1.		PDAC	is	seen	in	some	
breast	 cancer	 families	 with	 BRCA1	 and	 BRCA	 2	 mutations(Couch,	 Johnson	 et	 al.	
2007)	 and	 BRCA2	 may	 account	 for	 up	 to	 5%	 of	 all	 pancreatic	 cancers(Goggins,	
Schutte	 et	 al.	 1996).	 	 Patients	 with	 familial	 atypical	 multiple	 mole	 melanoma	
(FAMM)	due	to	p16	gene	mutations	have	a	9	to	47-fold	increased	risk	of	developing	
pancreatic	cancer	and	pancreatic	cancer	is	the	second	most	common	cancer	in	this	
syndrome(Lynch	 and	 Fusaro	 1991;	 Vasen,	 Gruis	 et	 al.	 2000).	 	 Peutz-Jeghers	
syndrome	 is	 an	 autosomal	 dominant	 syndrome	 characterised	 by	 harmartomatous	
polyps	of	the	GI	tract	and	melanocytic	macules	of	the	oral	mucosa	and	lips.		Patients	
with	 Peutz-Jeghers	 syndrome	have	 a	 high	 risk	 of	 developing	 pancreatic	 cancer	 as	
well	 as	 other	 malignancies	 of	 the	 gastrointestinal	 tract	 and	 breast	
cancer(Boardman,	 Thibodeau	 et	 al.	 1998;	 Hearle,	 Schumacher	 et	 al.	 2006).		








Syndrome	 Gene	defect	 Increased	 risk	
of	PDAC	












Chronic	 pancreatitis	 is	 a	 well-recognised	 risk	 factors	 for	 the	 development	 of	
pancreatic	cancer.	 	The	cumulative	25-year	 risk	of	pancreatic	cancer	 in	 individuals	
with	chronic	pancreatitis	has	been	quoted	at	around	4%(Lowenfels,	Maisonneuve	et	
al.	 1993).	 	 	 Lowenfels	 et	 al	 looked	 a	 large	 cohort	 of	 patients	 with	 chronic	
pancreatitis	 and	 showed	 a	 six	 times	 greater	 risk	 of	 development	 of	 pancreatic	
cancer	in	affected	individuals(Lowenfels,	Maisonneuve	et	al.	1993).	In	another	large	
case-control	 study	a	history	of	chronic	pancreatitis	or	acute	pancreatitis	 for	seven	





The	 association	 between	 pancreatic	 cancer	 and	 diabetes	 mellitus	 has	 been	
investigated	in	depth	as	both	a	causative	factor	and	a	feature	of	early	disease.	Large	
prospective	cohort	study	in	US	investigated	the	independent	association	with	post-
load	plasma	glucose	 concentration	 and	 risk	 of	 pancreatic	 cancer	mortality	 among	
individuals	without	 self	 reported	 diabetes.	 	 This	 study	 concluded	 that	 the	 factors	
associated	with	 abnormal	 glucose	metabolism	may	 play	 an	 important	 role	 in	 the	
aetiology	of	PDAC	(Gapstur,	Gann	et	al.	2000).	A	early	meta	analysis	found	a	relative	
risk	of	2.0	for	pancreatic	cancer	in	patients	with	at	least	a	5	year	history	of	diabetes	






number	 of	 studies	 dating	 back	 almost	 as	 far	 as	 30	 years(Gordis	 and	 Gold	 1984;	
Hirayama	1989).		There	is	a	clear	dose	response	noted	(Falk,	Pickle	et	al.	1988)	and	
risk	can	be	reduced	after	a	period	of	abstinence(Howe,	Ghadirian	et	al.	1992).	 	 In	
some	 case-control	 studies	 the	 risk	 of	 PDAC	 rises	with	 excessive	 lifetime	 cigarette	
consumption.		Being	a	smoker	and	having	a	first	degree	relative	with	PDAC	further	








The	 association	 between	 acute	 and	 chronic	 pancreatitis	 and	 heavy	 alcohol	
consumption	has	been	well	recognised	but	its	link	definitively	to	pancreatic	cancer	
has	 been	 somewhat	 elusive.	 	 	 The	 study	 evidence	 was	 reviewed	 by	 a	 panel	 of	
experts	in	2009	convened	by	the	Agency	for	research	on	cancer	(Secretan,	Straif	et	
al.	 2009).	 Previous	 studies	 including	 cohort	 studies	 and	 meta-analyses	 of	
prospective	studies	reported	significant	association	between	pancreatic	cancer	risk	
and	 alcohol	 consumption(Heuch,	 Kvale	 et	 al.	 1983;	 Heinen,	 Verhage	 et	 al.	 2009;	
Michaud,	 Vrieling	 et	 al.	 2010;	 Tramacere,	 Scotti	 et	 al.	 2010)	 but	 others	
demonstrated	no	association(Isaksson,	Jonsson	et	al.	2002;	Rohrmann,	Linseisen	et	
al.	2009).		These	previous	studies	lacked	convincing	evidence	owing	to	a	number	of	






associated	 with	 pancreatic	 cancer	 mortality	 in	 both	 non	 smokers	 and	 smokers	
specifically	in	spirit	consumption	but	not	wine	or	beer(Gapstur,	Jacobs	et	al.	2011).		
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Some	 studies	 have	 reported	 dietary	 factors	 as	 possible	 risk	 factors	 for	 the	























Over	 recent	 times	 there	 has	 been	 research	 that	 has	 provided	 a	 greater	




The	 development	 of	 pancreatic	 cancer	 has	 been	 well	 described	 as	 a	 stepwise	
process	 involving	 precursor	 lesions	 named	 pancreatic	 intraepithelial	 neoplasia	
(PanIN)	which	has	resulted	in	a	model	of	progression	of	these	lesions	to	pancreatic	
ductal	adenocarcinoma	shown	in	figure	1.1.		A	classification	based	on	morphologic	
features	 as	 been	developed	with	 three	 grades	 of	 PanIN	 lesions:	 PanIN-1,	 PanIN-2	
and	PanIN-3,	it	as	been	noted	that	PanIN-3	lesions	occur	in	association	with	PDAC	in	
around	 half	 of	 cases	 histologically	 examined,	 supporting	 the	 concept	 that	 high-
grade	PanIN	lesions	are	precursor	lesions	for	PDAC.	PanIN	lesions	are	found	in	the	
smaller	 pancreatic	 ducts	 (<5mm)	where	 the	 usual	 cuboidal	 flat	 epithelial	 lining	 is	
	 10	
replaced	by	columnar	mucinous	cells.		PanIN-1	lesions	are	classified	as	PanIN-1A	or	
PanIN-1B.	 	 In	 PanIN-1A	 the	mucinous	 epithelium	 is	 flat	 and	 in	 PanIN-1B	 papillary	
mucinous	 epithelium	 is	 present,	 both	 have	 minimal	 cytonuclear	 atypical	
appearances.		In	PanIN-2	lesions	there	is	a	greater	degree	of	cytonuclear	atypia	and	











analysis	 and	 common	 genetic	 mutations	 in	 these	 lesions	 and	 PDAC.	 	 In	 autopsy	
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studies	 an	 increased	 prevalence	 of	 PanINs	 was	 documented	 with	 increasing	 age	




documented	 PanIN	 lesions	 that	 went	 on	 to	 develop	 PDAC(Brat,	 Lillemoe	 et	 al.	
1998).	 	 The	 genetic	 and	 epigenetic	 mutations	 commonly	 found	 in	 PDAC	 are	
discussed	in	later	chapters	but	it	is	noted	that	common	mutations	occur	in		PanINs.		
Kras2	mutations	are	found	in	up	to	85%	of	PanIN-3	lesions(Lohr,	Kloppel	et	al.	2005)	
and	 mutation	 of	 the	 important	 tumour	 suppressor	 gene	 p16	 has	 also	 been	
documented	 in	 PanIN	 lesions(Wilentz,	 Geradts	 et	 al.	 1998).	 	 Positive	
immunostaining	 has	 been	 shown	 as	 a	 surrogate	 marker	 of	 mutation	 and	
inactivation	 of	 the	 p53	 tumour	 suppressor	 gene	 and	 has	 been	 demonstrated	 in	





genetic	 alterations	 that	 may	 play	 a	 role	 in	 this	 transition	 are	 still	 not	 clearly	
understood	or	mostly	unknown(Murphy,	Hart	et	al.	2013).		Investigation	of	genetic	
data	 has	 suggested	 there	 is	 nearly	 a	 12	 year	window	 from	 the	 earliest	 precursor	







Pancreatic	 ductal	 adenocarcinoma	 is	 the	most	 common	malignancy	 found	 in	 the	
pancreas.	 	 Solid	 tumours	with	poorly	demarcated	edges	being	characteristic.	 	 The	
majority	of	PDAC	tumours	are	well	to	moderately	differentiated	formed	by	tubular	




surrounding	 tissues.	 In	 moderately	 and	 poorly	 differentiated	 tumours	 there	 is	
increasing	 cellular	 irregularity	 poorly	 formed	 glands	 and	 decreased	 mucous	
production.	 	There	are	 further	malignant	 tumour	 types	of	 the	pancreas	which	are	
closely	 related	 to	 PDAC	 and	 considered	 variants	 of	 PDAC	 though	 these	 are	 less	



































diagnostically(Batge,	 Bosslet	 et	 al.	 1986;	 Takeda,	 Nakao	 et	 al.	 1991).	 	 Genetic	
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mutations	 in	Kras,	p16,	p53	and	SMAD4	can	often	be	demonstrated	 (discussed	 in	





the	 variable	 histological	 characteristic	 of	 tumours	 between	 tumours	 and	 within	
individual	 tumours	 initially	 in	 1985(Kloppel,	 Lingenthal	 et	 al.	 1985).	 	 Since	 then	
other	grading	systems	have	been	employed.		The	Japan	Pancreas	society	described	
a	 more	 complex	 system	 assigning	 grades	 for	 a	 variety	 of	 tissue	 structures	
(mizumoto	1996).			
	
The	 UICC	 recommendation	 is	 that	 the	 least	 favourable	 grade	 recorded	 in	 an	
individual	 tumour	 should	 be	 that	 assigned(Sobin	 and	 Fleming	 1997)	 and	 the	
International	 pancreatic	 cancer	 study	 group	 has	 recommended	 that	 the	
predominant	grade	and	any	other	observed	should	be	recorded.		From	the	various	
recommendations	it	remains	true	that	all	areas	of	the	tumour	should	be	examined	














The	 American	 Joint	 Committee	 on	 Cancer	 (AJCC)	 TNM	 classification	 is	 the	 most	
widely	 used	 system	 to	 stage	 PDAC	 and	 describes	 the	 anatomical	 extent	 of	 the	















































In	 PDAC	 lymph	 node	 involvements	 has	 been	 shown	 as	 a	 negative	 prognostic	

























its	 local	or	regional	extent.	Others	have	applied	 it	more	broadly	to	 include	distant	
metastasis.	The	specific	usage	should	be	indicated	when	the	R	is	used	





An	 overall	 staging	 of	 disease	 based	 on	 the	 TNM	 status	 provides	 a	 standardized	
classification	 system	 to	 determine	 appropriate	 treatment	 options	 and	 provide	
prognostic	information	from	the	time	of	diagnosis	(table	1.6).			Resectable	disease	is	
classed	as	stage	II,	borderline	stage	III	and	I	and	unresectable	or	advanced	is	stage	












Stage	0	 Tis	 N0	 M0	
Stage	IA	 T1	 N0	 M0	
Stage	IB	 T2	 N0	 M0	
Stage	IIA	 T3	 N0	 M0	
Stage	IIB	 T1,	T2,	T3	 N1	 M0	
Stage	III	 T4	 Any	N	 M0	
Stage	IV	 Any	T	 Any	N	 M1	
Table	1.6	 table	 showing	 the	overall	 stage	groupings	of	PDAC	based	on	 the	TNM	














van	 Mansfeld	 et	 al.	 1993).	 	 Mutations	 of	 KRAS	 affect	 codon	 12	 primarily	 but	
aberrations	 have	 also	 been	 found	 in	 codons	 13	 and	 61	 (19).	 	 The	 mutant	 KRAS	





Inappropriate	expression	of	 a	 variety	of	 growth	 factor	 receptors	 are	also	deemed	
important	 in	 PDAC.	 	 Epidermal	 growth	 factor	 receptor	 is	 a	 member	 of	 the	 ErbB	




domain.	 This	 results	 in	 phosphorylation	 of	 tyrosine	 residues	 on	 the	 intracellular	
domain	 providing	 docking	 sites	 for	 mediators	 activating	 downstream	 signalling	
pathways:	 including	 PI3K/Akt	 signalling	 pathway	 (mediating	 cell	 cycle	 progression	
and	 survival);	 Ras-Raf-MEK	 pathway	 (transmitting	 growth	 signals)	 and	 other	
pathways	 that	 facilitate	 a	 number	 of	 functions	 advantageous	 for	 cancer	 cell	
survival(Marshall	2006).		A	variety	of	other	growth	factor	receptors	and	their	ligands	
are	 expressed	 in	 PanIN	 lesions	 and	 PDAC	 including	 insulin-like	 growth	 factor	 and	
vascular	 endothelial	 growth	 factor	 (VEGF)	 receptor	 promoting	 endothelial	 cell	
proliferation	and	survival,	thereby	enhancing	tumour	angiogenesis.	VEGF	expression	
	 21	




Aberrant	 p16	 expression	 and	 namely	 alterations	 in	 the	 p16INK4A/retinoblastoma	
protein	 pathway	 affecting	 tumour	 suppressor	 genes	 has	 also	 been	 identified	 in	
PDAC.	 	 In	 PDAC	 the	 pathway	 is	 abrogated	 through	 functional	 inactivation	 of	 the	
INK4A	gene,	this	results	 in	a	 lack	of	 the	normal	suppression	of	phosphorylation	of	




The	 TP53	 tumour	 suppressor	 gene	 is	 the	 most	 commonly	 inactivated	 gene	 in	
cancers	 in	general	and	more	than	50%	of	pancreatic	cancers	 (Waddell,	Pajic	et	al.	
2015)..	 	 p53	 is	 usually	 activated	 in	 response	 to	 a	 range	 of	 cellular	 stresses	 and	
regulates	 transcription	 leading	 to	cell	 cycle	arrest	or	apoptosis.	 	Mutations	of	p53	
are	thought	to	occur	 in	the	 latter	PanIN	 lesions	and	aberrant	p53	to	contribute	to	














The	 Notch	 pathway,	 which	 is	 important	 developmentally	 in	 the	 pancreas,	 is	 also	
activated	 in	 the	 early	 stages	 of	 PDAC	 and	 is	 important	 in	 invasion(Leach	 2005;	
Lomberk,	Fernandez-Zapico	et	al.	2005).		Cell	surface	notch	receptors,	activated	by	
transmembrane	 ligands	 of	 the	 Delta	 and	 Jagged	 families,	 expressed	 on	









components	 of	 this	 pathway	 in	 PDAC	 that	 affects	 tumour	 growth	 as	 well	 as	
induction	 of	 stromal	 desmoplasia	 in	 PDAC,	 which	 contributes	 to	 the	
chemoresistance	 of	 PDAC(Kayed,	 Kleeff	 et	 al.	 2006;	 Bailey,	 Swanson	 et	 al.	 2008;	
Yauch,	Gould	et	 al.	 2008).	 	Although,	 trials	 of	 the	Hedgehog	 inhibitor	Vismodegib	














Figure	 1.2	 The	 12	 pathways	 and	 processes	 where	 component	 genes	 were	




One	 of	 the	 characteristics	 of	 pancreatic	 cancer	 is	 the	 formation	 of	 stroma	




maintenance	 of	 the	 tumour	microenvironment.	When	 in	 a	 quiescent	 state	 these	
cells	 are	 characterised	 by	 the	 expression	 of	 desmin,	 glial	 fibrillary	 acidic	 proteins	






























factor	 the	 fat	 droplets	 disappear;	 the	 stellate	 cells	 then	 express	 alpha-smooth	
muscle	actin	and	produce	collagen	fibres	that	make	up	a	dense	matrix	surrounding	
the	tumour(Mahadevan	and	Von	Hoff	2007).	 	This	not	only	provides	a	mechanical	
barrier	 to	 the	 tumour	 but	 also	 results	 in	 a	 relatively	 hypoxic	 poorly	 vascularised	
tumour;	both	of	 these	 factors	provide	a	 therapeutic	challenge(Erkan,	Reiser-Erkan	
et	al.	2009;	Masamune	and	Shimosegawa	2009).		Further	features	of	these	stromal	
cells	 have	 been	 associated	 with	 poor	 prognosis	 and	 resistance	 to	 treatment.		
Stromal	 cells	 are	 known	 to	 express	 PDGF	 receptor,	 vascular	 endothelial	 growth	
factor,	 chemokines,	 intergrins	 and	 hedgehog	 pathway	 components	 all	 of	 which	







of	 patients(Alexakis,	 Halloran	 et	 al.	 2004),	 the	 remainder	 presenting	 with	
unresectable	 disease.	 	 Even	 following	 a	 potentially	 curative	 resection,	 recurrence	
rates	are	high	owing	 to	 residual	macroscopic	disease(Sperti,	Pasquali	et	al.	 1997).			
In	 an	 effort	 to	 improve	 survival,	 more	 radical	 approaches	 to	 surgical	 resections	
including	 extended	 lymphadenectomy	 and	 total	 pancreatectomy	 have	 been	





The	 basis	 of	 current	 therapies	 for	 PDAC	 involves	 targeting	 of	 DNA	 replication	 by	
inhibition	 of	 thymidylate	 synthase	 and	 incorporation	 of	 fluorouridine	 derivatives	
into	 nascent	 DNA	 strands.	 	 The	 agents	 that	 are	 used	 are	 5-FU,	 capcetabine	 and	
gemcitabine	and	also	have	an	effect	on	transcription	and	DNA	methylation.		These	
therapies	 are	 used	 in	 both	 the	 adjuvant	 and	 advanced	 disease	 setting	 based	 on	
previous	trial	evidence.			
	
The	 ESPAC-1	 trial	 was	 instrumental	 in	 providing	 clear	 evidence	 for	 the	 role	 of	
adjuvant	chemotherapy	and	the	 lack	of	benefit	 from	chemoradiation	 in	 improving	
survival	following	resection	in	pancreatic	cancer(Neoptolemos,	Stocken	et	al.	2004).	
The	main	 finding	 from	 this	 study	was	a	median	 survival	of	20.1	months	 for	 those	
that	 received	 chemotherapy	 and	 15.5	months	 in	 those	 that	 did	 not	 (hazard	 ratio	
0.71,	 p=0.009).	 	 The	 results	 of	 CONKO-001	 trial	 has	 added	 more	 weight	 to	 this	
argument	 which	 randomised	 patients	 to	 adjuvant	 gemcitabine	 or	 observation	
following	 surgery,	 patients	 that	 received	 chemotherapy	 had	 a	 improvement	 in	
overall	median	survival	of	22.8	months	compared	to	20.2	months	in	the	observation	







in	 pancreatic	 cancer	 has	 been	 investigated	 and	 its	 use	 compared	 to	 gemcitabine.		
The	 JASPAC-01	trial	was	a	 randomised	controlled	study	that	enrolled	385	patients	
between	2007	and	to	2010.	 	The	use	of	adjuvant	gemcitabine	was	compared	to	S-
1(Maeda,	 Boku	 et	 al.	 2008).	 	 In	 2012	 interim	 results	 were	 published	 showing	 an	
overall	 2-year	 survival	 of	 53%	 for	 the	 gemcitabine	 group	 and	 70%	 for	 the	 S-1	
group(Fukutomi	2013).		The	disease	free	survival	was	also	noted	to	be	superior	for	
S-1	 at	 49%	 compared	 to	 29%	 in	 the	 gemcitabine	 arm.	 	 From	 this	 study	 the	
consideration	of	S-1	as	standard	adjuvant	treatment	was	suggested	and	is	now	the	
case	in	Japan	though	this	has	not	been	adopted	in	the	western	world,	this	is	due	to	




In	 2008	 Boeck	et	 al	published	 a	 systematic	 review	 and	meta-analysis	 of	 adjuvant	
chemotherapy	 in	 pancreatic	 cancer(Boeck,	 Ankerst	 et	 al.	 2007).	 	 Five	 trials	 were	







CI	 –4.6	 to	 10.8%,	 p<0.05).	 	 The	 authors	 supported	 the	 use	 of	 adjuvant	





This	 study	 concluded	 adjuvant	 therapy	 with	 either	 agent	 conferred	 a	 survival	
benefit	compared	to	observation	alone	(Hazard	ratios	0.68,	95%	CI:	0.44-1.07,	and	
0.62,	95%	CI:	0.42-0.88,	respectively).		It	was	noted	however	that	the	grade	3-4	non	
haematological	 toxicity	was	 far	greater	an	 issue	with	5-FU	 than	Gemcitabine(Liao,	
Chien	et	al.	2013).	
	
Currently	 the	 results	 of	 ESPAC4	 are	 set	 to	 change	 standard	 therapy	 after	 being	
released	 at	 the	American	 Society	 of	 Clinical	 oncology.	 	 ESPAC	 4	 is	 a	 international	
randomised	 control	 trial	 of	 combination	 adjuvant	 therapy	 (gemcitabine	 and	
capecitabine)	 versus	 single	 agent	 adjuvant	 therapy	 (gemcitabine).	 	 Although	 the	
median	 survival	 benefit	 was	modest	 in	 the	 combination	 group	 the	 overall	 5-year	
survival	for	this	group	was	double	that	of	the	gemcitabine	alone	cohort	(28.8%	vs.	
	 29	




In	 the	advanced	setting	 the	 initial	 standard	of	care	was	5-FU.	 	Evidence	 that	5-FU		
was	superior	to	best	supportive	care	was	demonstrated	by	a	meta-analysis	of	trials	
performed	between	1970	and	2003(Fung,	Takayama	et	al.	2003).		Subsequently	trial	
evidence	 supported	 the	 use	 of	 gemcitabine	 and	 its	 superior	 benefits	 in	 the	
advanced	 setting.	 	Burris	et	al	 showed	while	having	a	modest	 survival	 advantage,	
gemcitabine	 	 gave	better	 alleviation	of	 symptoms	 than	5-FU	 (Burris,	Moore	et	 al.	
1997).	 	 	 Sultana	et	al	 reviewed	 randomised	 control	 trials	 for	 advanced	pancreatic	
cancer	that	included	gemcitabine	or	5-FU	monotherapy,	gemcitabine	versus	5-FU	or	
gemcitabine/5-FU	 combination	 therapy	 with	 other	 chemotherapy.	 	 This	 meta-
analysis	 concluded	 that	 chemotherapy	 improved	 survival	 compared	 to	 best	
supportive	 care	 (hazard	 ratio	 =0.64,	 95%	 CI	 0.42-0.98),	 5-FU	 based	 combination	
therapy	was	not	superior	to	5-FU	alone,	there	was	no	significant	survival	difference	
between	 gemcitabine	 or	 5-FU	 but	 a	 definite	 improvement	 in	 survival	 from	
gemcitabine	combination	therapy	compared	with	gemcitabine	alone	(HR=0.91,	95%	
CI	 0.85-0.97).	 	 This	 meat-analysis	 supported	 the	 concept	 that	 gemcitabine	 based	




Capecitabine	 (xeloda)	 was	 developed	 to	 be	 an	 orally	 available	 form	 of	
fluoropryrimidine	 chemotherapy.	 Cunningham	 et	 al	 were	 able	 to	 show	 that	 a	
combination	 of	 capecitabine	 and	 gemcitabine	 (GEM-CAP)	 performed	 better	 than	
gemcitabine	 alone	with	 advanced	 disease,	 giving	 a	 genuine	 survival	 advantage	 in	
best-response	rates	(19.1%	v	12.4%,	p=0.03)	and	progression	free	survival	(HR	0.78;	




Further	 combinations	 with	 gemcitabine	 have	 been	 explored	 without	 improved	
efficacy.	 Gemcitabine	 and	 oxaliplatin	 or	 gemcitabine	 with	 cisplatin	 have	 been	
investigated	 in	 phase	 III	 trials	 though	 no	 statistically	 significant	 improvements	 in	
survival	 have	 been	 noted(Louvet,	 Labianca	 et	 al.	 2005;	 Colucci,	 Labianca	 et	 al.	
2010).	
A	 regimen	 referred	 to	 as	 GTX	 (docetaxel	 and	 capecitabine	 in	 addition	 to	
gemcitabine)	 has	 demonstrated	 some	 activity	 in	 the	 advanced	 disease	 setting	
though	with	a	degree	of	toxicity.	 	Phase	II	trials	showed	median	survival	of	25	and	
11	months	 for	patients	with	 locally	advanced	and	metastatic	disease	 respectively.		
Though	 not	 standard	 first	 line	 therapy	 this	 combination	 could	 be	 considered	 for	




Further	 combinations	 of	 gemcitabine	 with	 targeted	 therapies	 have	 yielded	 only	
small	(gemcitabine	plus	erlotinib)	or	no	survival	benefits	(cetuximab	or	bevacizumab	
plus)	with	 notably	 increased	 toxicities	 therefore	 currently	 these	 combinations	 are	
not	 used	 in	 standard	 therapy	 and	 offer	 no	 real	 benefit	 over	 gemcitabine	
alone(Moore,	 Goldstein	 et	 al.	 2007;	 Kindler,	 Niedzwiecki	 et	 al.	 2010;	 Philip,	
Benedetti	et	al.	2010).	
	
Recently	 there	 has	 been	 investigation	 of	 the	 FOLFIRINOX	 regimen	 in	 advanced	
pancreatic	 cancer	 (consisting	 of	 oxaliplatin,	 irinotecan,	 fluorouracil	 and	
leucovorin)(Conroy,	 Desseigne	 et	 al.	 2011).	 	 In	 this	 study	 the	 overall	 survival	was	
significantly	 better	 in	 the	 FOLFIRINOX	 group	 at	 11.1	 months	 compared	 to	 6.8	
months	 in	 the	gemcitabine	group	 (HR	0.57,	95%	CI	0.45-0.73,	p<0.001).	 	However	
more	 adverse	 event	 were	 noted	 in	 the	 FOLFIRINOX	 arm	 which	 had	 a	 significant	
effect	on	quality	of	 life	scores	making	the	combination	questionable	 in	the	setting	




The	 use	 of	 neoadjuvant	 therapy	 to	 improve	 the	 outcome	 for	 these	 patients	 by	
down-staging	 disease,	 increasing	 resection	 rates	 and	 R0	 resection	margins(Gillen,	















borderline	 resectable	 groups	 improvements	 in	 survival	 of	 up	 to	 a	 third	 are	
suggested.	 	 Studies	 to	 date	 consistently	 demonstrate	 an	 improved	 survival	 in	
borderlines	 receiving	 neoadjuvant	 therapy	 over	 non-resectable	 cases	 and	 even	
comparable	 survival	 to	 resectable	 cases	 which	 was	 supported	 in	 recent	 meta-
analyses(Gillen,	 Schuster	 et	 al.	 2010;	 Assifi,	 Lu	 et	 al.	 2011;	 Laurence,	 Tran	 et	 al.	
2011;	Andriulli,	 Festa	et	 al.	 2012).	A	 recent	prospective	 study	of	 a	 small	 group	of	
patients	 by	 Lee	 et	 al	 suggested	 curative	 resection	 is	 possible	 in	 patients	 with	
borderline	 resectable	 disease	 who	 undergo	 neoadjuvant	 therapy	 (Lee,	 Kim	 et	 al.	
2012).	
	
Further	 potential	 benefits	 of	 neoadjuvant	 therapy	 include	 possible	 increased	
efficacy	 of	 chemoradiation	 and	 chemotherapy	 to	 a	 well-vascularized	 and	
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oxygenated	tumour	as	well	as	identifying	patients	who	have	aggressive	disease	as	in	
this	 group	 of	 patients	 it	 has	 been	 demonstrated	 that	 surgery	 after	 neoadjuvant	




Despite	 the	 demonstrated	 survival	 benefits	 recurrence	 rates	 in	 resected	 disease	
remain	high	and	in	all	disease	settings	long-term	survival	remains	poor	due	in	part	
to	 chemoresistance.	 	 Cancer	 cells	 become	 resistant	 to	 therapy	 by	 a	 number	 of	
hypothesised	 means:	 by	 exclusion	 of	 drugs	 from	 the	 cancer	 cells,	 by	 changes	 in	
enzymes	 metabolising	 drug	 or	 by	 becoming	 resistant	 to	 apoptosis	 and	 cellular	
stress.		Further	increases	in	survival	should	be	possible	by	targeting	these	areas	that	
lead	 to	 resistance	 or	 targeting	 multiple	 pathways	 in	 combination	 with	 standard	
therapy.			
	
The	 lack	 of	 efficacy	 of	 current	 treatment	 may	 be	 explained	 by	 inadequate	 drug	
delivery	 to	 the	 cancer	 cells	 leading	 to	 ineffective	 concentrations.	 	 This	 may	 be	
attributable	 to	 the	 tumour	microenvironment	consisting	of	a	 stromal	extracellular	
matrix	protecting	cancer	 cells	or	 transport	of	 fluoropyrimidines	across	 the	plasma	
membrane	of	cancer	cells.		It	may	be	these	agents	are	not	transported	into	resistant	
cells	or	moved	out	more	 rapidly.	 	 There	are	 two	 types	of	nucleoside	 transporters	
that	 transport	 gemcitabine	 across	 the	 plasma	 membrane,	 namely	 equilabratitive	
(eNTs)	 and	 concentrative	 (cNTs)	 and	 there	 has	 been	 investigation	 into	 these	
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transporters	and	their	relationship	to	gemcitabine	resistance	although	cell	line	data	
has	 been	 inconclusive.	 	Gemcitabine	 is	 transported	by	 hENT1,	 hENT2	 and	hCNT1.	
Once	 gemcitabine	 enters	 a	 cell	 via	 eNTs	 it	 reaches	 equilibrium	 between	 the	
intracellular	 and	 extracellular	 compartments,	 cNTs	 increase	 the	 concentration	 of	
the	 drug	 intracellularly	 by	 accumulation	 against	 the	 concentration	 gradient.		
Marechal	et	al	observed	that	either	high	expression	of	eNT1	or	cNT	resulted	in	the	
best	overall	survival(Marechal,	Mackey	et	al.	2009)	and	the	high	expression	of	eNT1	
and	 the	 positive	 effect	 on	 survival	 was	 again	 supported	 in	 the	 RTOG-9704	
trial(Farrell,	Elsaleh	et	al.	2009).		However	contrary	finding	were	reported	by	Tsujie	
et	 al	 who	 demonstrated	 a	 direct	 liner	 relationship	 between	 the	 levels	 of	 eNT1	
mRNA	 and	 the	 IC50	 for	 gemcitabine	 and	 5-FU(Tsujie,	 Nakamori	 et	 al.	 2007).			
Interestingly	 in	 the	 research	 setting	 pancreatic	 cancer	 cell	 lines	 are	 sensitive	 to	
gemcitabine	 and	 5-FU	 regardless	 of	 eNT	 status	when	 adequate	 concentrations	 of	
drug	are	delivered	 to	 the	cell	membrane	which	goes	some	way	 to	explaining	why	
xenograft	 models	 show	 a	 good	 response	 to	 these	 agents.(Olive,	 Jacobetz	 et	 al.	
2009).		Conversely	in	transgenic	mouse	models	pancreatic	cancer	shows	resistance	
to	gemcitabine	similar	to	what	is	observed	in	the	clinical	setting	ad	this	seems	to	be	












observed	 in	 PDAC(Almoguera,	 Shibata	 et	 al.	 1988).	 	 The	 effects	 of	 farnesylation	
inhibitors	has	been	 investigated	owing	 to	 the	 fact	 that	 the	 ras	protein	undergoes	
farnesylation	 in	 order	 to	 adhere	 it	 to	 the	 plasma	 membrane.	 In	 early	 xenograft	
models	 promising	 effects	were	 observed.	 	Manumycin,	 one	 such	 agent,	 inhibited	
growth	in	a	xenograft	model	of	pancreatic	cancer	without	toxicity(Ito,	Kawata	et	al.	
1996).	 	 SCH	 66336,	 a	 small	 molecule	 farnesyl	 protein	 transferase	 inhibitor,	 was	
investigated	 in	 tumour	 xenograft	 models	 of	 colon,	 lung,	 pancreas,	 prostate	 and	
bladder	cancers.		In	these,	potent	oral	activity	was	observed	leading	to	a	reduction	
in	 tumour	 burden.	 	 The	 investigators	 went	 on	 to	 a	 transgenic	mouse	model	 and	
observed	 significant	 tumour	 regression	 in	 a	 therapeutic	 model	 associated	 with	
increased	 apoptosis	 and	 decreased	 DNA	 synthesis	 in	 tumours(Liu,	 Bryant	 et	 al.	
1998).	 	 Unfortunately,	 when	 entered	 into	 clinical	 trials	 these	 agents	 have	 so	 far	
been	ineffective(Macdonald,	McCoy	et	al.	2005).	This	may	be	due	to	the	fact	that	in	












metastatic	PDAC	were	enrolled	 into	each	arm.	 	 In	 the	primary	endpoint	of	overall	
survival	 there	was	no	 significant	benefit	 to	 combination	 therapy	 (HR	1.09,	95%	CI	
0.93-1.27,	 p=0.14)	 nor	 in	 secondary	 endpoints	 of	 Progression	 Free	 Survival	 (PFS)	
and	 response	 (philip	 2007).	 In	 clinical	 trails	 with	 pancreatic	 cancer	 erlotinib	 in	
combination	with	 gemcitabine	 showed	a	modest	 survival	 benefit	 in	 the	 setting	of	
advanced	cancer(Moore,	Goldstein	et	al.	2007).	
A	potential	target	in	pancreatic	cancer	is	that	of	VEGF	receptor	inhibitors.		One	such	
inhibitor	 is	 avastin	 (bevacizumab),	 which	 was	 studied	 in	 a	 phase	 II	 trial	 in	
combination	 with	 ertloinib	 and	 gemcitabine.	 	 The	 primary	 endpoint	 of	 6	months	
survival	 was	 not	 reached	 for	 most	 patients	 but	 stable	 disease	 was	 achieved	 for	
more	than	2	cycles	of	treatment	for	22.2%	of	the	patients(Ko,	Venook	et	al.	2010).		
A	 phase	 III	 trial	 into	 bevacizumab	 in	 combination	 with	 gemcitabine	 and	 erlotinib	
was	conducted.		Patients	with	metastatic	PDAC	were	assigned	to	gemcitabine	plus	
erlotinib	and	bevacizumab	or	placebo	with	the	primary	endpoint	of	overall	survival.		
In	 the	group	 that	 received	all	active	agents	 the	OS	was	not	 significantly	 improved	
compared	to	gem,	erlotinib	plus	placebo	but	the	therapy	was	well	tolerated	and	the	
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secondary	 endpoint	 of	 progression	 free	 survival	 was	 improved	 (HR	 0.73;	 CI	
95%0.61-0.86,	p=0.0002)(Van	Cutsem,	Vervenne	et	al.	2009).	
	
As	 previously	 discussed	 the	 relative	 resistance	 to	 current	 therapy	 may	 be	 the	
deficiency	in	apoptotic	features	in	cancer	cells.		Platinum	based	therapies	have	been	
shown	 to	 strongly	 stimulate	 apoptosis(Saif	 and	 Kim	 2007).	 	 Studies	 of	 platinum	
agents	in	pancreatic	cancer	have	shown	significant	benefit	when	these	are	used	in	
combination	with	gemcitabine.	 	The	combination	of	cisplatin	and	gemcitabine	has	
been	 shown	 synergistic	 in	 vitro	 and	 in	 a	 phase	 II	 study	 improvements	 where	
observed	 in	 disease	 free	 survival	 and	 response	 although	 there	was	 no	 significant	
difference	in	overall	survival	when	compared	to	gemcitabine	monotherapy(Colucci,	
Giuliani	et	al.	2002).		Another	such	phase	II	study	of	a	cisplatin	analog,	carboplatin,	
combined	with	 gemcitabine	 showed	 an	 encouraging	 1-year	 survival	 of	 28%(Xiros,	
Papacostas	et	al.	2005).		Combinations	with	both	gemcitabine	and	5-FU	have	been	
investigated	 with	 oxaliplatin	 and	 shown	 synergy	 in	 the	 pre-clinical	 setting.	 	 In	
patients	 with	 pancreatic	 cancer	 refractory	 to	 gemcitabine	 monotherapy,	 GEMOX	
has	 shown	 promising	 survival	 benefit(Demols,	 Peeters	 et	 al.	 2006).	 	 A	 similar	
suggestion	of	improved	survival	in	gemcitabine	refractory	tumours	has	been	shown	
with	the	combination	of	oxaliplatin	and	5-FU,	FOLFOX(Yoo,	Hwang	et	al.	2009).		In	a	
meta-analysis	 of	 novel	 combination	 therapy	 in	 PDAC,	 platinum	 agent	 based	




Targeting	 proteins	 that	 feature	 in	 the	 tumour	 stroma	 may	 also	 provide	 another	
therapeutic	 avenue.	 	 A	 study	 by	 Olive	 et	 al	 investigated	 a	 mouse	 model	 of	
pancreatic	cancer	 targeting	 the	stromal	hedgehog	pathway.	 	They	used	KPC	mice,	
which	conditionally	express	mutant	Kras	and	p53	in	PDAC	and	develop	tumours	that	





chemotherapeutic	 agents	 to	 the	 tumour(Olive,	 Jacobetz	 et	 al.	 2009).	 However,	 a	
clinical	 trial	 of	 hedgehog	 inhibition	 showed	 no	 improvement	 over	 gemcitabine	
alone		(Catenacci,	Junttila	et	al.	2015)	
	




p53	 and	 RB	 tumour	 suppressor	 pathways.	 	 With	 mutations	 in	 these	 pathways	
cancer	cells	overcome	checkpoints	and	the	genomic	instability	experienced	can	be	
attributed	 to	 the	 attrition	 of	 telomeres.	 	 In	 contrast	 to	 normal	 cells,	 cancer	 cells	
show	telomersase	activity	and	inhibition	can	lead	to	rapid	telomere	shortening	and	





has	 been	 shown	 to	 elicit	 T	 cell	 response	 in	 lung	 cancer	 without	 bone	 marrow	
suppression(Brunsvig,	 Aamdal	 et	 al.	 2006)	 and	 there	 was	 a	 phase	 I/II	 study	
conducted	 in	 unresectable	 pancreatic	 cancer	 to	 investigate	 safety	 and	
tolerability(Bernhardt,	 Gjertsen	 et	 al.	 2006).	 	 In	 this	 study	 a	 significant	 immune	
response	was	observed	in	75%	of	the	group	receiving	therapy.	The	vaccine	was	well	
tolerated	with	no	significant	adverse	effects.		In	this	study	overall	survival	was	not	a	
primary	 endpoint	 though	 a	 significant	 correlation	 was	 observed	 with	 median	
survival	 of	 8.6	 months	 in	 patients	 receiving	 a	 moderate	 dose	 compared	 to	 4.5	
months	in	those	receiving	a	low	or	high	dose.		After	300	days	all	surviving	patients	
had	 demonstrated	 an	 immune	 response	 to	 the	 vaccine.	 	 The	 TeloVac	 trial	 is	 the	
largest	study	of	GV1001	in	pancreatic	cancer	to	date	and	examined	gemcitabine	and	
capecitabine	 therapy	with	 concurrent	or	 sequential	GV1001	 treatment	 in	patients	




extracellular	 signal	 regulated	 kinase	 is	 a	 crucial	 component	 of	 the	 RAS-RAF-MEK-
extracellular	 signal	 regulated	 kinase	 (ERK)	 that	 has	 a	 role	 in	 several	 cellular	
processes	 and	 known	 to	 be	 aberrant	 in	 a	 number	 of	 cancers	 including	 pancreas,	
breast,	lung	and	colon(Hoshino,	Chatani	et	al.	1999).		A	MEK1/2	inhibitor,	CI-1040,	
demonstrated	 anti-proliferative	 activity	 in	 a	 xenograft	 model	 of	 pancreatic	
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cancer(Allen,	 Sebolt-Leopold	 et	 al.	 2003).	 	 In	 a	 phase	 I	 study	 of	 patients	 with	






cholecystokinin	 (CCK)/gastrin	 receptor	 and	 the	 gastrin	 precursor,	 progastrin,	 have	
been	 observed	 frequently	 in	 pancreatic	 tumours(Caplin,	 Savage	 et	 al.	 2000).		
Gastrin	 stimulates	 the	 proliferation	 of	 pancreatic	 cancer	 that	 can	 be	 inhibited	 by	
antisense	 oligonucleotides	 to	 gastrin(Smith,	 Fantaskey	 et	 al.	 1995;	 Smith,	
Verderame	 et	 al.	 1999).	 	 Gastrazole,	 a	 gastrin	 receptor	 antagonist	was	 studied	 in	
two	trials	in	pancreatic	cancer	compared	to	placebo	first	then	with	5-FU.		Compared	
to	placebo	median	survival	was	significantly	 improved	with	gastrazole	(7.9	months	
vs.	 4.5	 months)	 but	 there	 was	 no	 significant	 difference	 when	 compared	 to	 5-
FU(Chau,	Cunningham	et	al.	2006).	
	
Targeting	 the	 enzymes	 that	 allow	 cells	 to	 degrade	 their	 surrounding	 matrix	
therefore	 facilitating	 metastasis	 has	 provided	 another	 area	 of	 investigation	 in	
pancreatic	cancer.		Matrix	Metalloproteinase	(MMPs)	are	proteolytic	enzymes	that	
are	 involved	 in	 the	 degradation	 of	 the	 extracellular	 matrix	 and	 an	 association	
between	MMP	expression	 and	 tumour	 progression	 has	 been	 described(Chambers	
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and	 Matrisian	 1997).	 	 In	 pancreatic	 cancer	 MMP-2,-7,-8,-9	 and	 -11	 are	
overexpressed	 and	 high	 MMP-7	 levels	 correlate	 with	 a	 poor	 survival(Jones,	
Humphreys	et	al.	2004)	.		In	preclinical	models	MMP	inhibitors	have	shown	efficacy.		
SC44463,	 a	 novel	 MMP	 inhibitor	 prevented	 metastases	 in	 an	 early	 mouse	
model(Reich,	 Thompson	 et	 al.	 1988).	 	 A	 further	 MMP	 inhibitor	 Batimastat	 was	
investigated	in	a	orthotopic	murine	model	of	pancreatic	cancer	and	demonstrated	
reduced	metastasis	 and	 significantly	 prolonged	 overall	 survival	 as	 a	monotherapy	
and	 in	 combination	with	 gemcitabine(Zervox,	 Franz	 et	 al.	 2000).	 	 In	 clinical	 trials	
however,	 results	 were	 not	 as	 promising.	 	 A	 trial	 of	 patients	 with	 advanced	
pancreatic	 cancer	 treated	 with	 Tanomastat	 was	 terminated	 early	 as	 patients	
experience	 a	 significantly	 worse	 survival	 than	 those	 receiving	 placebo(Moore,	
Hamm	et	al.	2003).	Marimastat	has	been	extensively	investigated	in	human	trials	of	
pancreatic	cancer.		A	phase	II	study	showed	an	acceptable	toxicity	profile	and	some	
symptomatic	 improvement	 in	patients(Evans,	 Stark	et	al.	 2001)	 and	as	 a	 result	 of	
this,	 two	 randomised	phase	 III	 trials	were	 conducting	 comparing	gemcitabine	and	
Marimastat	 in	 patients	 with	 unresectable	 PDAC.	 	 In	 both	 of	 these	 no	 significant	
survival	benefit	was	seen	and	there	was	no	significant	improvement	in	combination	
therapy	 with	 gemcitabine	 when	 compared	 to	 gemcitabine	 alone(Bramhall,	
Rosemurgy	 et	 al.	 2001;	 Bramhall,	 Schulz	 et	 al.	 2002).	 	 It	 may	 be	 that	 this	 agent	
merits	 further	 investigation	 as	 study	 design	 was	 flawed:	 patients	 enrolled	 had	
advanced	 disease	 and	 the	 evidence	 from	 preclinical	 data	 in	 reducing	 progression	





COX-2	 plays	 a	 principal	 role	 in	 the	 metabolism	 of	 prostaglandins	 therefore	
mediating	 resistance	 to	 apoptosis,	 adhesion,	 motility,	 immunosuppression	 and	
angiogenesis	 (Trifan	 and	Hla	 2003)and	 has	 been	 shown	 to	 be	 expressed	 in	 up	 to	
90%	of	pancreatic	cancers(Okami,	Yamamoto	et	al.	1999).	Results	on	the	efficacy	of	
these	 agents	 in	 pancreatic	 cancer	 have	 been	 variable.	 	 In	 a	 phase	 I	 study	 of	
celecoxib	 with	 a	 gemcitabine-radiation	 regimen	 increased	 efficacy	 as	 well	 as	
significant	 toxicity	was	 observed(Crane,	Mason	 et	 al.	 2003).	 	 In	 another	 study	 by	
Milella	 et	 al	 no	 demonstrable	 clinical	 benefit	 was	 derived	 from	 the	 addition	 of	
celecoxib	 to	5-FU	therapy	 in	gemcitabine	refractory	disease(Milella,	Gelibter	et	al.	




the	 data	 thus	 far	 is	 conflicting	 the	 promising	 results	 that	 have	 been	 observed	
suggests	further	investigation	of	these	agents	in	pancreatic	cancer	is	warranted.	
	
Inhibitors	 of	 PI3K/AKT	 pathway	 have	 been	 suggested	 as	 potential	 agents.	 	 It	 has	
been	demonstrated	that	inhibition	of	the	AKT	pathway	in	pancreatic	cancer	induces	
apoptosis	and	restores	gemcitabine	chemosensitivity	in	vitro	offering	an	interesting	
therapeutic	 strategy(Ng,	 Tsao	 et	 al.	 2000;	 Bondar,	 Sweeney-Gotsch	 et	 al.	 2002).	







struggle	 to	 achieve	 such	 specificity	 and	 success	 has	 been	 marginal.	 Perhaps	 it	 is	
worth	considering	whether	this	apparent	virtue	is	truly	desirable.	
	





in	 combination	 with	 standard	 therapy	 may	 offer	 the	 most	 chance	 of	 making	
significant	 differences	 to	 survival	 of	 patients.	 	 A	 protein	 that	 appears	 on	multiple	
pathways	commonly	mutated	in	PDAC	is	Heat	Shock	Protein	(HSP)	90	and	may	offer	







The	 key	 to	 the	 future	 of	 chemotherapy	 in	 pancreatic	 cancer	 will	 be	 the	














then	 transfer	 of	 the	 terminal	 γ-phosphate	of	ATP	 to	hydroxyl	 residues.	 	 CDKs	 are	




























into	 two	daughter	 cells.	 	During	 S	phase	 chromosome	 replication	 takes	place	and	
during	M	phase	(mitosis)	segregation	of	the	replicated	chromosomes	occurs.		There	
are	 two	Gap	phases:	 the	phase	prior	 to	S	 is	G1	and	prior	 to	M	 is	G2.	 	The	double	
helix	 structure	of	DNA	unwinds	 in	 S	 phase	producing	 two	 templates	 used	 for	 the	
synthesis	of	two	new	DNA	strands.		In	G2	a	bipolar	spindle	is	formed	and	the	DNA	




point	 in	 the	 cell	 cycle.	 CDK4	 and	 6	 interact	 with	 cyclin	 D,	 CDK2	 with	 cyclin	 E,	
allowing	passage	through	the	G1	restriction	point	into	S	phase.		Phosphorylation	of	
Rb	 via	 cyclin	 D-CDK4/6	 late	 in	 G1	 phase	 results	 in	 the	 components	 necessary	 for	
DNA	 replication.	 	 Cyclin	 E-CDK2	 leads	 to	 further	 phosphorylation	 of	 pRb	 that	
facilitates	entry	to	S	phase.		Cyclin	A-CDK2	(and	then	CDK1)	prevents	re-initiation	of	
DNA	synthesis.	Completion	of	DNA	replication	 in	S	phase	 is	 followed	by	G2,	 there	
are	 3	 checkpoints	 that	 need	 to	 be	 passed	 in	 order	 to	 begin	 segregation	 of	
chromosomes	 at	 anaphase.	 First	 a	 checkpoint	 to	 ensure	 that	 there	 is	 no	 DNA	
damage	(the	DNA	checkpoint),	then	a	checkpoint	to	ensure	centrosome	segregation	
and	 correct	 spindle	 formation	 (the	 CHFR	 checkpoint)	 and	 then	 a	 checkpoint	 to	
ensure	that	the	chromosomes	are	correctly	orientated	at	the	metaphase	plate	(the	
spindle	 or	 tension	 checkpoint).	 These	 are	 controlled	 by	 cyclin	 B-CDK1,	 gradual	
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increase	 in	activity	allowing	metaphase	 to	be	achieved	and	 rapid	decline	allowing	




for	 cyclin	 B	 proteolysis	 and	 subsequent	 transition	 into	 anaphase.	 The	 cyclins	 and	





































to	 have	 loss	 of	 expression	 of	 a	 CDK	 inhibitor	 such	 as	 p16INK4a(Malumbres	 and	





Genetic	 alterations	 in	 CDKs	 themselves	 are	 not	 that	 common	 but	 have	 been	
observed	in	some	human	cancers.		Mutations	and	amplifications	in	CDK4	have	been	
noted	 in	 some	 tumours	 including	 melanomas,	 breast	 carcinomas,	 gliomas	 and	
sarcomas	(He,	Allen	et	al.	1994;	Wolfel,	Hauer	et	al.	1995;	Kanoe,	Nakayama	et	al.	




Deregulated	 expression	 of	 cyclins	 is	 a	 feature	 in	 human	 cancer,	 cyclin	 D1	 is	 of	
particular	 note	 and	has	 been	 identified	 in	 haematological	malignancies	 as	well	 as	
breast	cancers,	the	overexpression	of	cyclin	D1	is	involved	in	aberrant	Rb	pathways	









D1	 or	 deletion	 of	 p16INK4A	 activates	 the	 pRb	 pathway	 in	 this	 manner.	 	 p53	 is	 an	
essential	 regulator	 of	 the	 G1	 and	 G2	 checkpoints	 and	 arrests	 growth	 through	
induction	 of	 p21	 (a	 CDK	 inhibitor)	 and	 G2	 arrest	 by	 promoting	 transcription	 of	
GADD45	that	inhibits	cyclin	B-CDK1	activation.	
	
In	 pancreatic	 cancer	 a	 number	 of	 genetic	 abnormalities	 have	 been	 identified	
including	those	that	rely	on	or	are	closely	involved	in	cyclins	and	CDKs.		This	includes	
inactivation	of	 p16,	 a	 endogenous	CDK	 inhibitor.	 	 Cyclin	D	 synthesis	 and	 coupling	
with	 CDK	 partners	 is	 stimulated	 by	 growth	 factor	 signalling,	 under	 normal	
conditions	 p16	 normally	 prevents	 cell	 cycle	 progression	 by	 binding	with	 CDK	 and	
preventing	 the	 CDK	 phosphorylation	 of	 Rb.	 	 The	 drive	 into	 S	 phase	 is	 finally	
permitted	when	p16	 is	 sequestered	by	 the	production	of	 cyclin	D-CDK	 complexes	
allowing	 Rb	 phosphorylation	 and	 deactivation.	 	 This	 pathway	 (p16/Cyclin	 D/Rb)is	
critical	 in	 tumorigenesis(Sherr	 1996).	 	Mutation	of	 p16	 are	 frequent	 in	 pancreatic	
cancers	 the	majority	being	nonsense	mutations	 in	a	 single	allele	with	 silencing	by	
methylation	 of	 the	 other	 allele,	 the	 second	most	 common	 form	of	 inactivation	 is	
homozygous	deletions.			p15	activity	has	also	been	investigated	in	pancreatic	cancer	









Kras	 mutations	 are	 frequent	 and	 almost	 universal	 in	 pancreatic	 adenocarcinoma	
and	activity	of	ras	appears	central	to	pancreatic	tumorigenesis.	 	The	expression	of	
cyclin	 D1	 is	 regulated	 by	 ras,	 the	 elevated	 cyclin	 D1	 levels	 along	 with	 the	









































































Table	 1.8	 Table	 showing	 a)	 deregulated	 cyclins	 and	 CDKs	 and	 their	 associated	









The	role	of	aberrant	CDK	activity	and	potential	 inhibition	has	been	 investigated	 in	
many	human	cancers.	
	
Flavopiridol	 is	 broad-spectrum	CDK	 inhibitors	with	 proven	 activity	 in	 vitro	 against	
CDK1,	 2,	 4	 and	 6	 and	 cell	 effects	 including	 inhibition	 of	 growth	 and	proliferation,	
induction	of	apoptosis	and	 inhibition	of	angiogenesis.	 	 In	mouse	studies	poor	oral	
bioavailability	was	evident	and	subsequent	parenteral	dosing	did	result	in	some	GI	
and	marrow	 suppressive	 toxic	 effects	 but	 there	 was	 significant	 antitumor	 effects	
and	significantly	synergistic	effects	with	other	chemotherapeutics.	 	Phase	 I	clinical	
trials	 have	 been	 completed	 with	 flavopiridol	 as	 a	 monotherapy	 in	 refractory	




Yu	 et	 al	 performed	 a	 range	 of	 experiments	 concerning	 cyclin	 D-CDK4	 activity	 in	
Breast	 cancer.	 	 Initially	 they	 demonstrated	 that	 mice	 lacking	 in	 cyclin	 D1	 are	
resistant	to	breast	cancers	triggered	by	Erb-2	oncogene(Yu,	Geng	et	al.	2001)	then	
developed	 this	 hypothesis	 proposing	 that	 the	 ability	 of	 cyclin	 D	 to	 activate	 CDK4	
underpinned	 the	 oncogenic	 potential	 of	 Erb-2-driven	 breast	 neoplasia.	 	 This	 was	
tested	by	crossing	CDK4-null	mice	with	a	transgenic	strain	 in	which	the	expression	
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of	 Erb-2	 gene	was	 driven	 by	 a	mammary	 specific	mouse	mammary	 tumour	 virus	
enhancer.	 	 The	 result	 of	 this	 was	 complete	 protection	 against	 breast	 cancers(Yu,	
Sicinska	et	al.	2006).		Interestingly	the	normal	physiological	development	of	breast	
tissue	 in	the	CDK4-null	mice	was	unimpeded	suggesting	the	requirement	for	CDK4	
activity	 in	 neoplasia	 but	 not	 normal	 mammary	 development.	 	 These	 conclusions	
were	 supported	 by	 Landis	 et	 al	 (Landis,	 Pawlyk	 et	 al.	 2006)	 again	 supporting	 the	
concept	that	CDK’s	offer	an	attractive	target	in	cancer	therapy.	
	
Work	 on	 CDK2	 targeting	 has	 not	 provided	 such	 promising	 results.	 	 Testu	 et	 al	
investigated	CDK2	inhibition	and	noted	 its	activity	 is	 indispensible	for	both	colonic	












The	 effects	 of	 the	 CDK	 inhibitor	Dinaciclib	 (SCH727965;	MK-7965)	 in	 combination	
with	an	AKT	inhibitor	(MK-2206)	were	investigated	in	orthotopic	and	subcutaneous	
xenograft	models	of	pancreatic	cancer.		In	this	study	tumour	growth	and	metastases	






UK).	 	 This	 compound	 was	 developed	 using	 fragment-based	 X-ray	 crystallographic	
screening.	 	 Fragments	 are	 low-molecular	 weight	 compounds	 with	 low	 binding	
affinities	 and	 screening	 using	 X-ray	 crystallography	 yields	 small	 libraries	 of	
compounds	 that	 have	 much	 greater	 probability	 of	 yielding	 complimentary	
fragments	and	targets(Hartshorn,	Murray	et	al.	2005).		Astexs	developed	a	panel	of	
molecules	and	investigated	pharmacokinetic	properties	leading	to	the	identification	











lesser	 degree.	 	 Initial	 in	 vitro	 experiments	 across	 a	 range	 of	 cancer	 cell	 lines	
confirmed	 the	 antiproliferative	 (table	 1.9)	 activity	 of	 AT7519	 and	 TUNEL	 staining	
assays	 and	 colony	 formation	 confirmed	 induction	 of	 apoptosis	 in	 colonic	 and	





















































promise	 regarding	 efficacy.	 	 Patients	with	 refractory	 solid	 organ	 tumours	 or	 non-
Hodgkin’s	 lymphoma	were	enrolled	 and	 treated	with	 an	escalated	dose	based	on	







The	 role	 of	 CDKs	 and	 their	 inhibition	 in	 cancer	 including	 pancreatic	 cancer	 has	
shown	therapeutic	promise.		AT7519	a	general	CDK	inhibitor	has	shown	efficacy	in	a	
range	 of	 tumours	 in	 the	 pre	 clinical	 setting	 and	 therefore	 is	 agent	 that	 warrants	










folding	but	also	contributes	 in	a	host	of	other	 cellular	processes	 including	protein	












in	 the	mitochondria	and	GRP94	 in	 the	endoplasmic	 reticulum(Sreedhar,	Kalmar	et	
al.	2004).		The	ATP-binding	site	and	structural	conformity	is	conserved	from	bacteria	
to	man	 aside	 from	 a	 cross	 link	 between	 the	 N-terminal	 and	M-domain.	 	 The	M-
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domain	 is	 active	 in	ATP-hydrolysis	 and	 contains	 catalytic	 components	 for	 forming	




HSP90	 is	 a	 ATP-dependant	molecular	 chaperone	 functioning	 in	 a	 cycle	 associated	
with	ATP	binding	and	hydrolysis.	Structurally	HSP90	adopts	two	distinct	 functional	
conformities	that	are	 in	a	dynamic	equilibrium.	 	 In	the	 inactive	unbound	state	the	
protein	is	in	an	open	V-shaped	conformation.		The	binding	of	ATP	triggers	a	number	
of	 conformational	 changes	 and	HSP90	 reaches	 its	 compact,	 closed	 state.	 The	 fact	
that	these	states	are	in	dynamic	equilibrium	remains	important	functionally	as	this	
may	allow	HSP90	to	adapt	to	different	client	proteins	 (Li	and	Buchner	2013).	 	The	
protein	 binding	 region	 is	 located	 towards	 the	 C-terminal,	 it	 is	 the	 ATP	 hydrolysis	




the	ATP	hydrolysis	near	the	N-terminal	 results	 in	 the	conformational	changes	that	
clamp	 down	 onto	 the	 substrate.	 	 This	 ability	 of	 HSP90	 allows	 several	 functions	
including	 protein	 folding	 assistance,	 aggregation	 prevention	 and	 as	 a	 transport	
mechanism	 (Wegele,	 Muller	 et	 al.	 2004).	 HSP90	 functions	 as	 part	 of	 a	
multichaperone	complex	 in	association	with	cochaperones	and	client	proteins.	 	 In	




























In	 cancer	 biology	 client	 proteins	 have	 been	 identified	 that	 associate	with	 HSP90,	
those	described	 include	EGF	receptors,	MET,	Raf-1	kinase,	AKT,	mutant	p53,	CDK4	
and	 Bcr-abl(Maloney	 and	 Workman	 2002;	 Neckers	 and	 Ivy	 2003).	 	 These	 client	
proteins	 rely	on	HSP90	 for	 stabilisations	and/or	maturation	and	 contribute	 to	 the	
hallmarks	 of	 cancer,	 as	 described	 by	 Hanahan	 and	 Weinberg	 (Hanahan	 and	
Weinberg	 2000;	 Hanahan	 and	 Weinberg	 2011).	 	 The	 hallmarks	 include	 self-
sufficiency	 in	 growth	 signalling,	 insensitivity	 to	 anti-growth	 signalling,	 evading	
apoptosis,	sustained	angiogenesis,	metastasis	and	unlimited	proliferative	potential.		
In	pancreatic	cancer	12	pathways	that	are	routinely	mutated	have	been	described,	
observations	 showed	 some	 cancer	 had	 mutations	 in	 all	 these	 pathways	 and	 the	
majority	 had	 mutations	 in	 at	 least	 9	 (Jones,	 Zhang	 et	 al.	 2008).	 	 It	 follows	 that	
proteins	appearing	on	more	than	one	of	these	pathways	provide	interesting	targets	
for	therapy	and	it	is	noted	that	HSP90	is	required	for	all	of	these	pathways(Xu	and	
Neckers	 2007;	 Taldone,	 Gozman	 et	 al.	 2008).	 Pancreatic	 cancer	 remains	 a	
complicated	disease	possessing	multiple	 genetic	 changes.	Over	 90%	of	 pancreatic	
ductal	 adenocarcinomas	 have	 a	 mutation	 in	 the	 KRAS	 gene	 that	 restricts	 self-
inactivation	 (Eser,	 Schnieke	 et	 al.	 2014),	 its	 protein	 that	 can	 affect	 both	 the	
PI3K/AKT	and	MAP	kinase	pathways.	HSP90	client	proteins	AKT,	and	EGFR	are	both	
over-expressed,	amplified	or	activated	in	60%	(AKT2)	and	70%	of	pancreatic	cancers	
respectively(Ghaneh,	 Costello	 et	 al.	 2007).	 More	 generally	 both	 the	 MAP	 kinase	
pathway	 and	 the	 PI3K/AKT	 pathways	 have	 been	 associated	 in	 pancreatic	 cancer	


































































Figure	 1.7	 The	 multiple	 signalling	 pathways	 disrupted	 by	 HSP90	 inhibition	
disrupting	 both	 anti-apoptotic	 signalling	 and	 cell	 cycle	 progression.	 	 Targets	 of	




function:	 i.e.	 toxicity	 may	 be	 an	 issue.	 	 The	 therapeutic	 selectivity	 of	 HSP90	
inhibition	in	cancer	relies	on	a	number	of	factors	(Workman,	Burrows	et	al.	2007).		




in	 their	 normal	 state	 (Grbovic,	 Basso	 et	 al.	 2006).	 The	 cancer	 microenvironment	
IGF,%EGF,%PDGF%













(including	 acidosis	 and	hypoxia)	 is	 heavily	 influenced	by	molecular	 chaperones,	 in	
such	an	environment	HSP90	is	often	involved	in	large	muticomplexes	as	opposed	to	
the	 uncomplexed	 HSP90	 found	 in	 healthy	 cells.	 	 The	 inhibitors	 developed	 can	
specifically	 target	 the	 bound	 form	 of	 HSP90,	 such	 as	 17-AAG	 (Kamal,	 Thao	 et	 al.	
2003).	
	
Geldanamycin	 and	 its	 derivatives	 17-allyamino-geldamycin	 (17AAG)	 and	 17-
(dimethylaminoethylamino)-17-demethoxygeldanamycin	 (DMAG)	 are	 HSP90	
inhibitors	that	 initiated	 interest	 in	the	 inhibition	of	HSP90	as	a	strategy	for	cancer	
treatment.		Geldanamycin	is	a	benzoquinone	asamycin	that	has	been	shown	to	bind	
directly	with	HSP90	interfering	with	the	heterocomplex	formation	and	ATP	binding	
to	 the	 N-terminal	 resulting	 in	 ubiquitin	mediated	 proteasomal	 degradation	 of	 its	
client	 proteins(Workman,	 Burrows	et	 al.	 2007)	 (Whitesell,	Mimnaugh	et	 al.	 1994)	
(Grenert,	 Sullivan	 et	 al.	 1997).	 	 	 Despite	 the	 potent	 anti-tumour	 effects	
demonstrated	 by	 Geldamycin	 and	 17AAG	 their	 use	was	 limited	 by	 hepatotoxicity	
and	water	 solubility	 (Usmani2009)	 (Banerji,	 O'Donnell	 et	 al.	 2005).	 	 	 17-AAG	 has	
been	 investigated	 in	 prostate	 cancer	 and	 melanoma	 in	 a	 Phase	 II	 study	 but	 no	
objective	clinical	responses	were	seen	with	the	dose	and	scheduling	deemed	safe	in	
phase	I	studies	(Heath,	Hillman	et	al.	2008)	(Solit,	Osman	et	al.	2008).			17-DMAG	is	
a	 geldanamycin	 derivative	 with	 substitution	 of	 the	 C-17	 methoxy	 group	 that	
resulted	 in	 increased	water	 solubility	and	bioavailability	 (Hollingshead,	Alley	et	al.	
2005).	 	 In	phase	 I	 trials	clinical	responses	or	stable	disease	have	been	observed	 in	
prostate,	 melanomas	 and	 renal	 cell	 carcinomas	 but	 again	 drug-related	 toxicities	
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and	 its	 co-chaperone	 Cdc37.	 This	was	 investigated	 by	 Zhang	et	 al	using	 celastrol,	
they	 demonstrated	 inhibition	 of	 cell	 division	 and	 induction	 of	 apoptosis	 in	






number	 of	 other	 agents	 have	 been	 developed	 based	 on	 this	 initial	 prototype	
molecule	and	advanced	 to	clinical	 trials.	 	CNF2024/BIIB021	as	one	such	agent	has	
been	 investigated	 in	 phase	 I	 and	 II	 clinical	 trials	 in	 advanced	 solid	 organ	
malignancies,	 toxicities	 included	 grade	 3	 and	 4	 fatigue,	 hyponatreamia	 and	
hypoglycaemia	and	efficacy	investigation	demonstrated	stable	disease	in	11	of	the	
16	patients	studied	(Saif,	Takimoto	et	al.	2014).	
Another	 HSP90	 inhibitor	 that	 has	 been	 investigated	 is	 novobiocin	 although	 this	
inhibition	 	 was	 an	 additional	 effect	 not	 originally	 expected.	 	 Novobiocin	 is	 a	





of	 client	 proteins(Donnelly	 and	 Blagg	 2008).	 	 The	 activity	 of	 novobiocin	 itself	 in	
relation	 to	 HSP90	 inhibition	 was	 weak	 therefore	 a	 number	 of	 analogues	 were	
developed	that	have	shown	more	promising	anti-cancer	activity	(Burlison,	Neckers	
et	 al.	 2006).	 	 Montori	 et	 al	 demonstrated	 one	 such	 analogues	 activity	 in	 breast	
cancer	 cell	 lines(Montoir,	 Barille-Nion	 et	 al.	 2016)	 as	 well	 as	 other	 literature	
demonstrating	 novobiocin	 analogues	 activity	 in	 lung	 and	 breast	 cancer	 cell	
lines(Hall,	Seedarala	et	al.	2016)	
	
























vitro	 and	 in	 vivo	models.	 	 Smyth	et	 al	 investigated	AT13387	 activity	 against	 an	 in	
vitro	and	in	vivo	gastrointestinal	stromal	tumour	model	and	found	it	effective	both	
in	 Imatinib	 (standard	 therapy)	 sensitive	 and	 resistant	 cell	 lines,	 notably	 AT13387	
was	effective	in	cell	lines	resistant	to	17-AAG,	an	alternative	HSP90	inhibitor	(Smyth,	
Van	Looy	et	al.	2012).			As	a	result	of	these	initial	investigations	a	randomised	phase	





Graham	et	al	demonstrated	AT13387	efficacy	 in	 	a	xenograft	model	of	 	 refractory	
non-small	 cell	 lung	 cancers	 demonstrating	 significant	 reduction	 in	 tumour	 growth	
compared	to	controls	and	noted	a	long	duration	of	action	both	 in	vitro	and	 in	vivo	
(Graham,	 Curry	 et	 al.	 2012).	 	 Currently	 phase	 I	 and	 II	 clinical	 trials	 have	 been	




More	 recently	AT13387	has	been	demonstrated	 to	overcome	 issues	 in	melanoma	
relating	 to	 clinical	 resistance	 to	 BRAF	 inhibitors	 in	 pre-clinical	 studies	 (Smyth,	
Paraiso	et	al.	2014)	and	further	drug	safety	in	a	phase	I	clinical	trial	of	patient	with	
advanced	 solid	 organ	 tumours	 has	 demonstrated	 safety	 and	 tolerability	 with	
preliminary	 anti-tumour	 activity	 (Shapiro,	 Kwak	 et	 al.	 2014).	 	 Current	 phase	 II	











































the	 complex	 molecular	 events	 seen	 in	 this	 disease.	 	 AT13387	 as	 a	 novel	 HSP90	
inhibitor	 presents	 a	 new	 agent	 that	 warrants	 investigation	 in	 PDAC	 in	 the	 pre-



















The	 aim	 of	 this	 study	 was	 to	 evaluate	 two	 novel	 agents	 in	 pancreatic	 cancer,	
AT7519,	 a	 general	CDK	 inhibitor,	 and	AT13387,	 a	HSP90	 inhibitor	as	 single	agents	
and	in	combination	with	standard	therapy	(gemcitabine).		The	actions	of	each	agent	
alone	and	 in	 combination	with	 standard	 chemotherapy	 (gemcitabine)	 in	 vitro	was	















6. Western	 blotting	 was	 undertaken	 to	 measure	 biomarkers	 related	 to	





in	nude	mice	and	the	cell	 line	 that	produced	tumours	most	amenable	 to	a	
xenograft	model	was	taken	forward	to	further	studies.	
2. AT7519,	 AT13387	 and	 gemcitabine	were	 assessed	 for	 tolerability	 as	 single	
agents.	
3. Responses	 to	 AT13387,	 AT7519	 and	 gemcitabine	 were	 assessed	 as	 single	
agents	against	control	animals	measured	by	tumour	volume.	
4. AT7519	 +	 gemcitabine	 and	 AT13387	 +	 gemcitabine	 were	 assessed	 for	
tolerability	in	combination.	
5. Responses	 to	AT7519	and	AT13387	 in	 combination	with	gemcitabine	were	



















AT7519	was	provided	by	Astex	Pharmaceuticals	 (Cambridge,	UK).	 	 Powered	agent	
was	 diluted	 in	Dimethyl	 sulfoxide	 (DMSO)	 	 (Sigma,	 Poole,	UK)	 to	 a	 stock	 solution	






































































































































Khaled	 Dajani	 (Department	 of	 Molecular	 and	 Clinical	 cancer	 medicine)	 and	 a	
subsequent	 clonal	 population	 developed	 by	 Elisabeth	 Shaw	 (Cancer	 Research	
	 79	
Centre	 UK,	 Liverpool).	 	 SUIT-2	 cells	 were	 rendered	 gemcitabine	 resistant	 by	 sub-
culturing	with	progressively	 increasing	concentrations	of	gemcitabine	 to	a	plateau	










All	 tissue	culture	work	was	undertaken	 in	a	 class	 II	hood	with	 laminar	 flow	which	
was	cleaned	with	70%	ethanol	prior	to	use.	 	Tissue	culture	reagents	(RPMI	media,	
PBS	and	Trypsin,	all	from	Sigma,	Poole,	UK)	were	warmed	in	a	37oC	water	bath	for	
15	minutes	prior	 to	use	and	bottles	cleaned	with	70%	ethanol	prior	 to	transfer	 to	













Cells	 contained	 in	a	T25	or	T75	 flask	had	RPMI	media	 removed	and	 the	adherent	
cells	were	 lavaged	with	 10ml	 of	warmed	 PBS,	which	was	 subsequently	 discarded	
into	virkon.	 	Trypsin	was	 then	 introduced	 into	 the	 flask,	1ml	per	T25	and	2ml	per	
T75,	 and	 the	 flask	 returned	 to	 the	 incubator	 for	 the	 time	 required	 to	 lift	 the	
adherent	 cells	 from	 the	 surface.	 	 	 After	 this	 period	 of	 time	 flasks	 were	 removed	
from	the	incubator	back	to	the	hood	and	trypsin	diluted	with	RPMI	media	to	make	a	
total	volume	of	10ml	(i.e.	9ml	of	media	per	T25	and	8ml	of	media	per	T75).	 	Cells	


































(Sigma,	 Poole,	 UK)	 and	 spun	 in	 a	 centrifuge	 at	 500rpm	 for	 5	minutes.	 	 Next	 the	
	 82	
media	was	removed	from	the	resultant	cell	pellet	and	then	this	was	resuspended	in	








All	 cells	 lines	 used	 were	 verified	 as	 the	 correct	 line	 by	 genotyping	 via	 PCR	
















was	 added	 to	 each	 100µl	 well	 and	 absorbance	 readings	 were	 taken	 from	 0	 to	 4	
hours	 at	 hourly	 intervals	with	 incubation	 at	 37oC	 between	 readings.	 	 These	were	
taken	on	a	microtiterplate	reader	set	at	450nm	with	620nm	as	a	reference	used	to	













at	 the	 required	 density	 in	 100µl	 in	 96	 well	 plates	 and	 incubated	 for	 24	 hours.	
Subsequently	the	media	was	removed	a	fresh	media	with	varying	concentrations	of	
drug	were	added	and	plates	then	incubated	for	24,	48,	36,	72	and	96	hours	at	which	











Isobolar	 analysis	 of	 drug	 combination	were	 completed	 for	Gemcitabine	 +	AT7519	
and	Gemcitabine	+	AT13387.	 	The	concentrations	of	agent	used	were	determined	
from	 the	 single	 agent	 IC50’s	 and	 the	 IC50	 was	 used	 as	 the	 0.25x	 or	 0.5x	













































































































































IC50).	 	 Cells	 were	 seeded	 in	 96	 well	 plates	 at	 previously	 determined	 optimum	














































Cell	 cycle	 analysis	was	 completed	 on	 pancreatic	 cancer	 cell	 lines	 using	 untreated	





































































































































































Both	 adherent	 and	 floating	 cells	were	 collected	 and	washed	with	 twice	with	 PBS	




	Propidium	 iodide	 incorporation	was	 using	 assessed	 using	 a	 CyAn™	 ADP	 Analyzer	
















RPMI	 media	 was	 removed	 and	 fresh	 media	 with	 either	 10μM	 AT7519,	 1μM	




Caspase-Glo	 reagent	 was	 added,	 as	 detailed	 in	 the	manufacturers	 protocol	 using	
100ul	 volumes	 and	 incubated	 for	 1	 hour.	 Luminescence	was	 then	measured	 in	 a	







Western	 blot	 analysis	 was	 completed	 on	 pancreatic	 cancer	 cell	 line	 lysates.		




The	 antibodies	 used	 as	 potential	 downstream	 markers	 in	 western	 blotting	 were	
supplied	by	Cell	 Signalling	 Technology	 via	New	England	Biolabs	 ltd,	Hertfordshire,	
UK.	
The	antibodies	used	for	AT7519	were	cdc2,	pp1-α,	phospho-pp1-α,	Rb,	phospho-Rb,	
NPM	and	phospho-NPM	 (table	 2.5).	 	 Cdc2	 antibody	detects	 endogenous	 levels	 of	
cdc2	protein,	which	encodes	 for	CDK1.	 	Pp1-α	and	 its	phosphorylated	version	are	
involved	 in	 cell	 cycle	 regulation.	 	 Pp1-α	 dephosphorylates	 Rb	 and	 cdc25	 during	





nucleus	 and	 an	 elevated	 level	 is	 often	 found	 in	 tumour	 cells.	 	 NPM	had	multiple	
functions	 including	 centresome	 duplication	 as	 a	 substrate	 of	 CDK2/cyclinE,	 its	














Cdc2	 34kDa	 9112	 Rabbit	 1	in	
2000	
5%	BSA	 5%	BSA	





38kDa	 2581S	 Rabbit	 1	in	
1000	
5%	BSA	 5%	BSA	





120kDa	 44-574G	 Rabbit	 1	in	
1000	
5%	BSA	 5%	BSA	






















HSP70*	 70kDa	 SPA-811	 Rabbit	 1	in	
1000	
5%	BSA	 5%	BSA	
S6	 32kDa	 2317	 Rabbit	 1	in	1000	 5%	Milk	 5%	Milk	
Phospho-
S6	
32kDa	 4838	 Rabbit	 1	in	1000	 5%	Milk	 5%	Milk	
CDK	4	 30kDa	 2906	 Mouse	 1	in	1000	 5%	Milk	 5%	Milk	
Akt	 60kDa	 9272	 Rabbit	 1	in	1000	 5%	BSA	 5%	BSA	
Phospho-
Akt	
60kDa	 4058	 Rabbit	 1	in	1000	 5%	BSA	 5%	BSA	












cells	 in	media	 transferred	 into	a	 falcon	 tube	and	 spun	 for	2	minutes	ay	1000rpm.		
The	media	was	removed	from	the	cell	pellet	and	this	was	resuspended	in	PBS	and	
transferred	 to	 a	 1.5ml	 eppindorf	 tube.	 	 This	 was	 centrifuged	 at	 1000rpm	 for	 2	
minutes,	the	PBS	was	then	removed	and	the	cell	pellet	resuspended	in	50-100µl	of	
SDS	lysis	buffer	dependant	on	the	size	of	the	cell	pellet	obtained.		The	cell	lysis	was	





assay.	 	 The	 Bradford	 assay	 is	 a	 colorimetric	 protein	 assay	 which	 is	 based	 on	 the	
























These	 standards	 and	 the	 cell	 lysates	 to	 be	 analysed	 were	 then	 placed	 in	 to	
eppendofs		with	2µl	of	the	sample,	200µl	of	Bradford	assay	and	798µl	of	dH2O.	 	A	
blank	 with	 800µl	 of	 dH2O	 and	 200µl	 of	 Bradford	 assay	 was	 also	 made	 and	 was	
measured	 first	 to	 calibrate	 the	 machine	 then	 the	 standards	 and	 samples	 were	
measured	using	a	spectrophotometer	set	at	562nm.		The	BSA	standards	were	then	








of	 western	 or	 the	 day	 before	 and	 stored	 at	 -20oC	 overnight.	 	 The	 determined	
volume	 of	 cell	 lysate	 was	 added	 to	 3µl	 of	 loading	 buffer	 (sample	 loading	 buffer	
ingredients	given	below	in	table	2.8)	and	a	variable	volume	of	1xRBS	(dependent	on	
the	volume	of	cell	lysate	used)	to	make	a	total	volume	of	15µl	in	a	100µl	eppendof.		
































for	 a	 further	 20	minutes	 approximately.	 	 Gels	 were	made	 fresh	 the	 day	 prior	 to	



























5ul	 of	 protein	 ladder	 was	 loaded	 into	 that	 far	 left	 lane	 then	 samples	 loaded	
alongside	 from	 left	 to	 right.	 	 Samples	were	 then	 allowed	 to	 run	 on	 the	 gel	 using	
35Amp	output	for	approximately	1.5	hours	until	the	proteins	had	run	down	to	the	
bottom	of	the	gel.	

















Species-specific	 secondary	 antibody	 was	 then	 introduced	 and	 incubated	 for	 1.5	




Membranes	 were	 immersed	 in	 5ml	 of	 Enhanced	 Chemiluminescence	 (ECL)	
detection	solution	for	5	minutes.	 	This	was	then	removed	and	membranes	blotted	
dry	and	loaded	into	a	Kodak	light	safe	exposure	cassette	and	exposed	onto	medical	




















times,	 15	 minutes	 per	 wash.	 	 Secondary	 anti-mouse	 Horseradish	 Peroxidase-
Conjugated	(HRP)	antibody	was	introduced	in	5%	milk/PBS	at	a	concentration	of	1	in	
3000	for	1.5	hrs.		A	further	round	of	4	15	minute	PBS	washes	were	then	performed	














A	 mouse	 xenograft	 model	 with	 pancreatic	 cancer	 cell	 lines	 was	 planned	 to	 test	
AT7519,	AT13387	and	gemcitabine	as	single	agents	and	the	combination	of	AT7519	
+	 gemcitabine	 and	 AT13387	 +	 gemcitabine.	 	 The	 animal	 licensee	 course	 was	
undertaken	(University	of	Liverpool)	and	a	personal	licence	obtained	(PIL	40/9684).		
The	experiments	where	carried	out	in	accordance	with	project	licence	PPL40/3320	
and	 all	 experiments	 designed	 under	 the	 obligations	 of	 the	 Animals	 in	 scientific	

















experiments	 in	 the	 xenograft	 model.	 	 As	 the	 initial	 experiment	 would	 be	











They	were	 suspended	 in	10ml	of	warmed	RPMI	media	 and	 spun	 in	 a	15ml	 falcon	
tube	 at	 200rpm	 for	 5	minutes.	 	 The	media	was	 then	 removed	 and	 the	 cell	 pellet	
resuspended	 into	 20ml	 of	 RPMI	media	 and	 incubated	 in	 a	 T75	 flask.	 	 Cells	 were	
incubated	 for	 4	days	 at	 37oC	 in	5%	CO2	and	 then	 split	 to	1	 in	10	 in	 the	 standard	
method	 described	 in	 section	 2.3.2.	 	 The	 day	 before	 planned	 injections	 cells	
	 102	




then	were	 trypsinised	with	 2ml	 of	 trypsin	 per	 T75	 flask.	 	Once	 trypinsied	 6mls	 of	
media	was	added	 to	each	 flask	 to	make	a	 total	 volume	of	8ml.	 	 Flasks	were	 then	









was	 combined	with	 the	 same	 volume	 of	Matrigel	 HESC	Matrix	 (Bectin	 Dickinson,	
Oxford,	UK)	which	had	undergone	a	slow	defrost	overnight	on	ice	and	the	mixture	






Nude	 mice	 were	 supplied	 by	 Charles	 River	 UK,	 BALB/c-Nude	 mice	 CAnN.Cg-
Foxn1nu/Crl.		This	strain	of	immunodeficient	mouse	was	developed	through	crosses	
and	 backcrosses	 between	 BalB/caBom-nu	 and	 BalB/cannCrj-nu	 at	 Charles	 River	





commencing	 the	 study	 and	 then	 ear	 punched	 to	 differentiate	 between	 animals	
(figure	3.1).		They	were	weighed	daily	and	monitored	for	any	changes	in	behaviour	
that	might	indicate	poor	health.		In	tolerability	studies	animals	were	not	dosed	with	
agents	 if	 they	 had	 >15%	weight	 loss	 compared	with	 animal	weight	 on	 day	 0	 and	
were	culled	 if	 they	had	sustained(72	hrs.)	weight	 loss	of	>20%.	 	 In	efficacy	studies	






Figure	 3.1	 A	 figure	 showing	 the	 rodent	 ear	 punch	 identification	 map	 used	 for	
experiments.	
	
In	 the	 xenograft	 model	 tumours	 were	 measured	 thrice	 weekly	 with	 external	
callipers,	 taking	measurements	of	 length,	width	 and	height.	 	Measurements	were	
standardised	 by	 being	 taken	 by	 only	 one	 individual	 through	 all	 studies	 and	






kidneys	and	 spleen)	which	were	 suspended	 in	 formaldehyde	 for	H	&	E	 staining	 in	
tumour	bearing	mice	tumours	were	resected	also.		The	tumours	were	measured	in	
vivo	 and	 ex	 vivo	 and	 weighed	 ex	 vivo.	 	 The	 tumours	 were	 then	 divided	 in	 half	





Animals	were	 culled	 by	 a	 schedule	 1	method	 (CO2	 asphyxiation)	 at	 the	 specified	
experimental	end	point	or	when	the	following	circumstances	arose:	













tested.	 	Cell	 lines	were	prepared	for	 injection	as	per	the	methodology	of	restoring	
cell	 lines	 detailed	 in	 section	 3.1.2.	 	 4	 mice	 per	 cell	 line	 were	 inoculated	 with	
tumours	 to	 both	 left	 and	 right	 shoulders	 with	 200ul	 of	 the	 tumour	 suspension.		
	 106	
Mice	 were	 observed	 daily	 and	 once	 palpable	 tumours	 were	 established	





Weight	measurements	 and	 general	 well-being	 observations	 were	 also	 performed	
daily.	 	 The	 experimental	 endpoints	 were	 tumours	 reaching	 the	 maximum	 mean	
diameter	 of	 17mm	 or	 28	 days	 from	 inoculation	 with	 tumours.	 	 Post	 culling	 the	





AT7519	and	AT13387	 for	 in	vivo	 studies	were	provided	by	Astex	Pharmaceuticals,	







AT7519	was	provided	as	 the	methanesulphonic	 salt	of	 the	 compound.	 	Doses	are	




Calculations	 of	 doses	 were	 based	 on	 a	 20g	mouse	 and	 enough	 agent	 for	 7	 days	
treatment	 was	 made	 up	 on	 each	 occasion.	 	 One	 injection	 at	 7.5mg/kg	 was	
0.1875mg	 per	 100ul	 for	 the	 base	 and	 0.223mg	 per	 100ul	 for	 the	 salt.	 	 The	 salt	
weight	was	multiplied	by	the	number	of	injections	required	and	the	amount	of	salt	
required	was	established.		An	excess	of	50%	was	added	to	this	weight	to	account	for	

























per	 100µl	 for	 the	 base	 and	 1.95mg	 per	 100µl	 for	 the	 salt.	 	 	 2-Hydroxypropyl)-β-














































on	 current	 literature.	 	 Tolerability	 experiments	 were	 performed	 in	 non-tumour	
bearing	mice.			
	
3	 mice	 per	 group	 were	 given	 intra-peritoneal	 injections	 of	 agents	 and	 had	 daily	
monitoring	 of	 weight	 and	 behaviour	 to	 establish	 tolerability.	 Gemcitabine	 was	
tested	at	100mg/kg	twice	per	week,	AT7519	at	7.5mg/kg	twice	daily	for	5	days	and	
AT13387	at	80mg/kg	once	weekly;	all	for	2	weeks	(table	3.1).		Drugs	were	deemed	














Animals	 were	 injected	 with	 Miapaca2	 pancreatic	 cancer	 cell	 lines	 into	 the	 right	
shoulder	 as	 in	 section	 3.1.2.	 	 Once	 tumours	were	 palpable	 thrice	weekly	 calliper	
measurements	 were	 undertaken.	 	 	 Drug	 injections	 commenced	 one	 week	 after	
measurements	began.		Animals	were	treated	for	3	weeks.	 	Each	group	constituted	
of	six	animals	and	each	drug	was	tested	against	a	vehicle	control	group.		All	agents	
were	 dosed	 at	 the	 previously	 determined	maximum	 tolerated	 dose;	 Gemcitabine	
100mg/kg	twice	weekly,	AT13387	80mg/kg	once	weekly	and	AT7519	7.5mg/kg	BD	
for	 5	 of	 7	 days.	 	 Vehicle	 control	 groups	 included	 saline	 BD	 for	 5	 of	 7	 days	 and	
cyclodextrin	 once	weekly.	 	 Table	 3.2	 summaries	 the	 treatment	 groups	 used.	 	 The	
experimental	 endpoint	 was	 tumours	 reaching	 the	 maximum	 mean	 diameter	 of	
15mm,	weight	 loss	 of	 >20%	 sustained	 over	 72	 hours	 or	 completion	 of	 treatment	
(these	 animals	 were	 usually	 retained	 for	 a	 maximum	 of	 4	 days	 after	 treatment	












study	 a	 tolerability	 experiment	 was	 performed.	 	 Tolerability	 experiments	 were	














AT13387	 and	 gemcitabine	 were	 tested	 in	 combination	 three	 times	 with	 varying	























Table	 3.5	 A	 table	 showing	 the	 dosing	 regime	 of	 the	 	 AT7519	 +	 Gemcitabine	
combination	efficacy	experiments.	
	









extracted	 from	 animals	 at	 necropsy	 and	 immediately	 fixed	 in	 paraformaldehyde.		
Later	 these	 tissue	 sections	 were	 dehydrated	 further	 with	 successive	 ethanol	
washes,	embedded	 in	paraffin	and	sectioned	with	a	microtome	(by	pathologist	Dr	





Results	 were	 maintained	 on	 excel	 spreadsheets	 and	 statistical	 analysis	 was	
performed	using	excel	 and	 statsbase.	Median	 tumour	volume	between	 treatment	











Initial	 experiments	 performed	 were	 to	 establish	 the	 ability	 of	 agents	 to	 inhibit	
growth	of	pancreatic	cancer	cell	lines	in	vitro.		The	results	of	novel	agents	AT7519,	
AT13387	and	the	standard	therapy	gemcitabine	are	included.		Inhibition	of	growth	





lines.	 	 The	 half	 maximal	 inhibitory	 concentration	 (IC50)	 was	 determined,	 as	 a	
quantitative	measure	of	how	much	of	the	drug	was	needed	to	inhibit	cell	growth	by	
half	using	MTS	assay	as	a	measure	of	cell	viability.		Cells	were	cultured	at	a	seeding	
density	 of	 1.5	 x	 104,	 incubated	 for	 24	 hours	 and	 then	 treated	 with	 increasing	
concentrations	 of	 Gemcitabine	 (500nM	 –	 1nM,	 1000nM	 –	 5nM	 for	 SUIT-2	 GR	







tested.	 	 IC50	 values	 ranged	 from	625nM	 to	 5nM.	 	 In	 a	Gemcitabine	 resistant	 cell	
line,	SUIT-2	(GR),	IC50	values	obtained	were	markedly	increased	compared	with	the	
other	 cell	 lines	 tested	 confirming	 this	 to	 be	 a	 resistant	 line.	 	 	 Figures	 4.1	 and	 4.2	
show	 the	 growth	 curves	 for	 the	parent	 line	 SUIT-2	 and	 gemcitabine	 resistant	 line	
SUIT-2	 (GR).	 	 Cell	 photography	 shown	 in	 figure	 4.3	 again	 demonstrates	 the	

















points	 represent	 the	 gemcitabine	 concentration	 used),	 the	 Y-axis	 shows	 the	













































































































Figure	4.2	A	graph	 showing	growth	curves	of	 cell	 viability	 corrected	 for	 controls	
after	 treatment	 with	 variable	 concentrations	 of	 gemcitabine	 in	 SUIT-2	 (GR)	
pancreatic	 cancer	cell	 line.	The	X-axis	 shows	 the	gemcitabine	concentration	 (the	
plotted	data	points	represent	the	gemcitabine	concentration	used,	error	bars	are	


















































The	 ability	 of	 AT7519	 to	 inhibit	 growth	 was	 assessed	 in	 6	 pancreatic	 cancer	 cell	
lines.	 	 After	 seeding	 in	 96-well	 plates	 cells	 were	 cultured	 with	 increasing	
concentrations	of	AT7519	(50nM-5000nM)	and	MTS	assay	was	performed	on	plates	
at	 24,	 48	 and	 72	 hours.	 	 Experiments	 had	 6	 replicates	 and	 were	 performed	 in	
triplicate	and	growth	 curves	plotted	 to	determine	 the	 IC50.	 	 The	72	hour	 reading	
IC50	values	are	shown	in	Table	4.2.		Growth	curves	and	determined	IC50	values	are	
shown	 in	 figures	4.4	and	4.5	 	 	Cell	photography	shown	 in	 figure	4.6	demonstrates	
the	 inhibition	 of	 cell	 growth	when	 treated	with	 AT7519	 in	 comparison	 to	 control	
plates.	
	




































Figure	 4.5	 Graph	 showing	 growth	 curves	 of	 cell	 viability	 corrected	 for	 controls	
after	 treatment	 with	 variable	 concentrations	 of	 AT7519	 in	 SUIT-2	 (GR).	 X	 axis	
shows	AT7519	concentration	(plotted	data	points	represent	AT7519	concentration	




















AT7519	 inhibited	 proliferation	 across	 a	 range	 of	 pancreatic	 cancer	 cell	 lines	 with	
IC50	values	ranging	from	180nM	to	2μM.		The	gemcitabine	resistant	line	SUIT-2	(GR)	
was	more	sensitive	than	the	parent	 line	to	AT7519	offering	encouraging	results	to	







The	 ability	 of	 AT13387	 to	 inhibit	 growth	was	 assessed	 in	 7	 pancreatic	 cancer	 cell	
lines.		After	seeding	in	96-well	plates	at	1.5	x	104	cells	were	cultured	with	increasing	
concentrations	of	AT13387	(5mM	-	5nM)	and	MTS	assay	was	performed	on	plates	at	




cell	 line	 SUIT-2	 (GR)	 and	 the	 parent	 line	 SUIT-2	 had	 comparable	 sensitivity	 to	
AT13387.	 	SUIT-2	(GR)	was	significantly	more	sensitive	to	treatment	with	AT13387	
than	gemcitabine.	 	 	Experiments	had	6	replicates	and	were	performed	in	triplicate	
and	 growth	 curves	 plotted	 to	 determine	 the	 IC50.	 	 	 Cell	 photography	 shown	 in	
figure	4.9	demonstrates	the	inhibition	of	cell	growth	when	treated	with	AT13387	in	
comparison	 to	 control	 plates.	 	When	 experiments	 were	 performed	 removing	 the	























after	treatment	with	variable	concentrations	of	AT13387	 in	SUIT-2	cell	 line.	 	The		
72	hour	 reading	 is	 shown.	The	X	axis	 shows	AT7519	concentration	 (plotted	data	







Figure	 4.8	 A	 graph	 of	 growth	 curves	 of	 cell	 vitality	 corrected	 for	 controls	 after	
treatment	with	 variable	 concentrations	 of	 AT13387	 in	 SUIT-2	 (GR)	 cell	 line.	 	 An	
MTS	assay	was	performed	at	2,	24,	48	and	72	hours.	The	X	axis	 shows	AT13387	







































































































































AT13387	 inhibited	 proliferation	 in	 a	 range	 of	 pancreatic	 cancer	 cell	 lines	 and	 the	
sensitivity	of	a	gemcitabine	resistant	line	SUIT-2	GR	was	comparable	to	that	of	the	
parent	 line	 in	 contrast	 with	 the	 marked	 resistance	 to	 gemcitabine	 observed	























Figure	 4.11	Bar	 chart	 of	 percentage	of	 SUIT-2	 cells	 at	G1	peak	phase	of	 the	 cell	
cycle	untreated	or	treated	with	gemcitabine	at	7,	24	and	48	hours.	X	axis	shows	





























Following	24	hours	 treatment	with	AT7519	 there	was	 clear	 arrest	 in	G2/M	phase	














Figure	 4.13	A	 bar	 chart	 of	 percentage	 of	 SUIT-2	 cells	 in	 phases	 of	 the	 cell	 cycle	
treated	 with	 AT7519	 (10μM)	 versus	 untreated	 control	 cells	 7	 hours	 after	 drug	






























Cell	 cycle	analysis	 showed	a	marked	 reduction	of	 cells	 in	 the	G0/G1	and	S	phases	





The	effect	of	AT13387	 treatment	on	cell	 cycle	progression	was	assessed	 in	SUIT-2	
cells.	SUIT-2	cells	were	seeded	onto	6	well	plates	at	2.5	x	105	cells	per	well	in	RPMI	









































Figure	4.17	A	bar	 chart	of	 the	percentage	of	 cells	 in	different	phases	of	 the	 cell	
cycle	treated	with	AT13387	versus	untreated	control	SUIT-2	cells	at	24	hour	time	










































Evidence	 of	 induction	 of	 apoptosis	 by	 gemcitabine	 was	 tested	 in	 Miapaca-2	
pancreatic	 cancer	 cell	 line	by	 investigation	of	 caspase-3	activity.	 	 The	 caspase-Glo	
3/7	luminescent	assay	was	performed	on	cells	treated	with	250nM	of	Gemcitabine	
or	0.1%	DMSO	control	at	6,	16,	24,	40,	48	and	72	hours.	 	At	40,	48	and	72	hours	





















































Evidence	of	 induction	of	apoptosis	by	AT7519	was	 tested	 in	Miapaca-2	pancreatic	
cancer	 cell	 line	 by	 investigation	 of	 caspase-3	 activity.	 	 The	 caspase-Glo	 3/7	



















































but	 this	 does	 not	 necessarily	 equate	 to	 cell	 death	 therefore	 investigation	 was	
undertaken	 to	establish	 if	 apoptosis	was	occurring	using	 caspase	3/7	activity	 as	 a	
marker	of	this.		After	treating	Miapaca-2	cells	with	1μM	of	AT13387	or	0.1%	DMSO	








Figure	 4.21	 A	 bar	 chart	 showing	 the	 caspase-3	 activity	 of	 untreated	 and	
AT13387(1μM)	treated	Miapaca-2	pancreatic	cancer	cells	at	6,	16,	24,	40,	48	and	
72	 hours.	 The	 x-axis	 shows	 time	 point	 of	 assay	 after	 treatment	 and	 the	 y-axis	
shows	RLU-normalised	to	untreated	control	cells.	**	p<0.01.	
	
This	 observed	 evidence	 of	 apoptosis	 was	 further	 confirmed	 by	 the	 presence	 of	
cleaved	PARP	in	Miapaca-2	cells	at	30		and	48	hours	after	treatment	,	it	was	noted	











































After	 establishing	 the	 IC50	 values	 for	 gemcitabine,	 AT7519	 and	 AT1387	 as	 single	
agents	the	combinations	of	gemcitabine	+	AT7519	and	gemcitabine	+	AT13387	were	







was	 introduced	 with	 variable	 concentrations	 of	 gemcitabine	 (20nM-2.5nM)	 and	
AT7519	 (2μM	–	0.25μM)	with	wells	of	 combined	agents,	 single	 agents	 and	media	
controls.	 MTS	 assays	 were	 performed	 at	 24,	 48,	 36,	 72	 and	 96	 hours.	 	 IC50	
experiments	were	performed	in	triplicate	with	4	plates	per	experimental	run.	
	
When	gemcitabine	 and	AT7519	were	 added	 in	 combination	 the	 resulting	 isobolar	
curve	 generated	 showed	 an	 antagonistic	 effect.	 	 	 These	 initial	 results	 showed	
AT7519	 still	 had	 an	 effect	 at	 its	 recognized	 IC50	 regardless	 of	 the	 presence	 of	






Figure	 4.22	A	 graph	 showing	 an	 isobolar	 analysis	 of	 the	 combination	of	AT7519	
and	gemcitabine.	Data	is	shown	from	6	96-well	plates	representing	the	average	of	
50%	 point	 of	 cell	 growth	 across	 plates	 adjusted	 for	 controls.	 	 The	 AT7519	
concentration	used		ranged	from	2-0.25	μM	and	gemcitabine	was	20-2nM.		Both	
agents	 were	 added	 to	 plates	 at	 the	 same	 time	 point.	 	 The	 x-axis	 shows	
gemcitabine	 concentration	 in	nM	and	 the	y-axis	 shows	AT7519	 concentration	 in	
μM.	 	Plotted	red	and	blue	points	represent	the	50%	 isoeffect	 i.e.	 the	amount	of	
each	agent	required	to	produce	a	50%	cell	growth	inhibition.	Points	plotted	along	
the	black	 line	would	 represent	 an	 additive	 effect,	 points	 above	 the	 line	 suggest	
antagonism		and	below	the	line	represent	synergy.	
	
In	 light	 of	 this	 results	 further	 experiments	were	 performed	 using	 sequential	 drug	
addition.		From	data	generated	after	discussion	it	was	decided	that	the	addition	of	











Following	 this	 sequential	 addition	 of	 drugs	 and	 isobolar	 curve	 was	 generated	









μM	 and	 gemcitabine	 concentrations	 used	 were	 20-2nM.	 	 The	 x-axis	 shows	
gemcitabine	 concentration	 in	nM	and	 the	y-axis	 shows	AT7519	 concentration	 in	
μM.	 	Plotted	red	and	blue	points	represent	the	50%	 isoeffect	 i.e.	 the	amount	of	
each	agent	required	to	produce	a	50%	cell	growth	inhibition.	Points	plotted	along	
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isobolar	 analysis,	 however	 when	 the	 scheduling	 of	 the	 agents	 was	 modified	 to	
sequential	 addition	 of	 gemcitabine	 then	 the	 combination	 of	 gemcitabine	 and	
AT7519	an	additive	effect	was	observed.		This	supports	the	cell	cycle	data	observes	







hours,	 fresh	 media	 was	 then	 introduced	 with	 variable	 concentrations	 of	




The	 combination	of	AT13387	 and	 gemcitabine	did	 not	 yield	 an	 adequate	 isobolar	
analysis.		In	one	run	of	the	experiment	gemcitabine	did	not	have	a	significant	effect	
as	a	single	agent	and	in	2	runs	AT13387	did	not	have	an	effect	as	a	single	agent,	this	















In	 order	 to	 establish	 the	 downstream	 targets/effects	 of	 treatment	 with	 AT7519	
western	 blotting	 was	 performed	 on	 a	 number	 of	 downstream	 targets	 both	 to	
demonstrate	activity	and	to	establish	any	potential	biomarkers	 for	the	AT7519.	 	A	










After	 treatment	 with	 AT7519	 as	 a	 single	 agent	 (dose	 1μM-10μM)	 western	 blot	




Figure	 4.24	 A	 figure	 showing	 the	 western	 blot	 assay	 of	 protein	 extracts	 from	
pancreatic	 cancer	 cell	 line	Miapaca-2	 treated	with	 AT7519	 (1μM-	 10μM)	media	
























































Figure	 4.25	 A	 figure	 showing	 a	 western	 blot	 assay	 of	 protein	 extracts	 from	









that	 cells	need	 to	be	dividing	 in	order	 for	a	G2/M	block	 to	occur	 (figure	4.26	and	
4.27).	
	







































        AT7519             Gemcitabine 
cdc2 Β actin 34kDA 




Figure	 4.26	 A	 figure	 showing	 combination	 treatment-	 a	 western	 blot	 assay	 of	







extracts	 from	 pancreatic	 cancer	 cell	 line	 Miapaca-2	 treated	 with	 gemcitabine	
(25nM)	 +	 	 AT7519	 (250nM	 –	 2μM).	 	 Gemcitabine	 was	 given	 for	 24	 hours	 then	
AT7519	for	24	hours.	The	blot	was	probed	with	cdc2	(CDK1)	antibody.		


















































Combis: 25nM Gemcitabine and desired concentration of AT7519 added together 
Sequential: Cells treated with 25nM of Gemcitabine for 24h followed by the addition of the 
desired concentration of AT7519.  
34kDA CDK1 


















































Combis: 25nM Gemcitabin  and desired concentration of AT7519 added together 
Sequential: Cells treated with 25 M of Gemcitabine for 24h followed by the addition of the 
desired concentration of AT7519.  
34kDA CDK1 
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After	 treatment	 with	 AT7519	 as	 a	 single	 agent	 levels	 of	 cdc2	 activity	 were	
unchanged.	 In	 combination	 AT7519	 and	 gemcitabine	 displayed	 a	 cdc2	 decrease,		





dysfunctional	 in	 cancer.	 	Rb	prevents	excessive	 cell	 growth	by	 inhibiting	 cell	 cycle	
progression	 from	G1	 to	 S	 phase	 until	 a	 cell	 is	 ready	 to	 divide	 at	which	 point	 it	 is	















































































Protein	 phosphatase	 type	 1	 (pp1)	 is	 one	 of	 the	 major	 cellular	 serine/threonine	
protein	phosphatases	and	has	a	crucial	role	in	cell	cycle	progression.		The	activity	of	
Rb	in	turn	is	regulated	by	phosphorylated	pp1-α.		 Its	phosphorylation	is	controlled	














































































Nucleophosim	 (NPM)	 plays	 important	 roles	 in	 the	 regulation	 of	 cell	 proliferation	
and	apoptosis	and	has	been	found	abundant	in	tumour	cells.		The	phosphorylation	
of	 NPM	 is	 facilitated	 by	 cyclin	 E/CDK2	 which	 is	 a	 precursor	 step	 to	 centrosome	
duplication.	
	
Western	 blot	 analysis	 was	 performed	 with	 NPM	 and	 phosphor	 NPM	 antibodies	
using	 cells	 that	 had	 been	 treated	 with	 AT7519	 or	 gemcitabine	 (experiements	
performed	by	Owain	Jones).		Results	showed	whilst	NPM	levels	were	unchanged	by	





Figure	4.32	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	 Miapaca-2	 treated	 with	 AT7519	 (250nM-2μM)	 or	 gemcitabine	 (10nM	 –	


































































































































































Western	 blotting	 was	 performed	 in	 order	 to	 establish	 the	 downstream	
targets/effects	 of	 treatment	 with	 AT13387.	 	 A	 number	 of	 potential	 targets	 were	




important	 for	 the	 growth	 and	 survival	 of	 cancer	 cells.	 This	 includes	 molecules	
involved	in	cell	survival,	growth	and	cell	cycle	progression.	We	examined	the	effect	
of	AT13387	inhibition	on	a	number	of	these	proteins	including	those	involved	in	the	


















Miapaca-2	 cells	 were	 treated	 with	 AT13387	 for	 18	 hours.	 	 This	 resulted	 in	
significantly	 decreased	 levels	 of	 phosphor	 Akt	 and	 decreased	 levels	 of	 Akt	 with	
increasing	concentrations	of	AT13387	(figure	4.34).	
	
Figure	4.34	A	western	blot	 assay	of	protein	 extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	 treated	with	 AT13387	 (10nM-	 1000nM)	 or	media	 control	 for	 18	
hours.	The	blots	were	probed	with	Akt	and	phospho	Akt	antibody.			
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.









AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared




























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
Suit-2GR  Control 
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
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AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
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• Pancreatic cancer continues to have a poor pr gnosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
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When	Miapaca-2	 cells	were	 treated	with	 AT13387	 plus	 gemcitabine	 it	was	 noted	
that	 decreased	 concentrations	 of	 Akt	were	 observed	 both	when	 the	 agents	were	




Figure	 4.35	 Figure	 showing	 combination	 treatment	 –	 A	 western	 blot	 assay	 of	
protein	extracts	from	pancreatic	cancer	cell	line	Miapaca-2	treated	with	AT13387	
(1.	 10nM,	 2.	 25nM,	 3.	 100nM,	 4.	 250nM,	 5.	 1000nM)	 or	 AT13387	 with	








Figure	4.36	A	 figure	showing	the	sequential	addition	of	agents	 	 -	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 Gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	





and	Phospho	Akt.	 	When	 cells	were	 treated	with	both	AT13387	 and	Gemcitabine	








Phosphorylation	 of	 the	 S6	 ribosomal	 protein	 correlates	 with	 increases	 mRNA	
transcripts	 that	 encode	 for	 proteins	 involved	 in	 cell	 cycle	 progression	 and	 factors	








Figure	4.37	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	




























Figure	4.39	A	 figure	 showing	 the	sequential	addition	of	agents	–	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	




















HSP90	 is	 essential	 for	 raf-1	 protein	 stability	 and	 it	 localization	 in	 the	 cell.	 	 Raf-1	
activation	 initiates	 the	MAPK	 (mitogen-activated	 protein	 kinase)	 cascade	 that	 has	
critical	 regulatory	 functions	 in	 determining	 cell	 proliferation,	 differentiation,	








Figure	4.40	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	 treated	with	 AT13387	 (10nM-	 1000nM)	 or	media	 control	 for	 18	
hours.	The	blot	was	probed	with	Raf-1	antibody.			
	 170	
The	 combination	 of	 gemcitabine	 and	 AT13387	 showed	 similar	 effects	 to	 that	 of	








Figure	 4.41	A	 figure	 showing	 combination	 treatment	 of	 agents	 -	 A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	single	agent	or	AT13387	with	gemcitabine	 (500nM)	 for	18	hours.	G	 represents	








Figure	4.42	A	 figure	 showing	 the	sequential	addition	of	agents	–	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	















CDK4	protein	 is	 a	member	of	 the	 cyclin	dependent	kinase	 family	of	enzymes	 that	
has	 been	 found	 to	 be	 associated	with	 tumourgenesis	 in	 a	 variety	 of	 cancers	 and	
forms	a	complex	with	HSP90	and	cdc37.	
	




Figure	4.43	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.









AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared



























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
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progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
Suit-2GR  Control 
































Time from injection of cells (days)
Before AT13387
After AT13387





































Time from injection of cells (days)
Before Vehicle
After Vehicle
Inhibition of tumour growth in a pancreatic cancer xenograft model by 
AT13387, a novel Hsp90 inhibitor.
Elisabeth Shaw1, Amy Thomas1, Paula Ghaneh1, William Greenhalf1, Michael Davies1, Eithne Costello1, Fiona 
Gibbs1, John Lyons2, John Neoptolemos1, D. Ross Sibson1.
1Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of 
Liverpool;  2 Astex Pharmaceuticals Ltd., Cambridge, UK. *email: e.j.shaw@liv.ac.uk
\
ACKNOWLEDGEMENTS
We would like to thank Astex Pharmaceuticals for advice and access to AT13387. Many thanks to
Dr Carol Walker for her advice and technical expertise at the start of this project. This research
was funded by Clatterbridge Cancer Research, the Liverpool Experimental Cancer Medicine
Centre and NIHR Pancreatic Biomedical Research Unit.
• Ad inistered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regressi n) w reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 d G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.









AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared


























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
Suit-2GR  Control 
































Time from injection of cells (days)
Before AT13387
After AT13387











































The	 combination	 of	 AT13387	 and	 gemcitabine	 showed	 similar	 effects	 to	 that	 of	
AT13387	 alone	 (figure	 4.44).	 	 Again	 when	 gemcitabine	 and	 AT13387	 were	 given	
sequentially	 the	 same	 decreased	 protein	 expression	 was	 observed	 but	 this	 was	
noted	at	decreased	concentrations	of	AT13387	(figure	4.45).	
	
Figure	 4.44	A	 figure	 showing	 the	 combination	 treatment	 of	 agents	 –	 A	western	
blot	assay	of	protein	extracts	 from	pancreatic	cancer	cell	 line	Miapaca-2	treated	
with	 AT13387	 (1.	 10nM,	 2.	 25nM,	 3.	 100nM,	 4.	 250nM,	 5.	 1000nM)	 or	 media	









Figure	4.45	A	 figure	 showing	 the	sequential	addition	of	agents	–	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 Gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	




AT13387	 reduced	 the	 protein	 expression	 levels	 of	 CDK4,	 the	 effect	 on	 protein	














times	 of	 cellular	 stresses,	 including	 oncogenic	 transformation.	 	 HSP70	 is	 a	 co	
chaperone	to	HSP90	inhibition.	
	




Figure	4.46	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	 treated	with	 AT13387	 (10nM-	 1000nM)	 or	media	 control	 for	 18	
hours	which	was	probed	with	HSP70	antibody.		
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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[1] P. Workman, Cancer Letters 2004; 206, 149-157
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.









AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared




























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
Suit-2GR  Control 
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When	 Miapaca-2	 cells	 were	 treated	 with	 AT13387	 plus	 gemcitabine	 the	 same	






of	 protein	 extracts	 from	 pancreatic	 cancer	 cell	 line	 Miapaca-2	 treated	 with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	single	agent	or	AT13387	with	gemcitabine	(500nM)	for	18	hours.	G18	represents	










Figure	4.48	A	 figure	 showing	 the	sequential	addition	of	agents	–	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	




Cells	 treated	 with	 AT13387	 showed	 upregulation	 of	 HSP70	 protein	 compared	 to	














































which	would	 generate	 a	measurable	 tumour	 that	would	 grow	over	 an	 acceptable	




methodology	 section	 3.1.2.	 	 Four	 mice	 per	 group	 were	 inoculated	 with	
subcutaneous	tumours	to	each	shoulder	(see	table	5.1	and	5.2).	
	
Mice	 were	 injected	 on	 day	 0	 and	 observed	 for	 up	 to	 28	 days.	 	 Tumour	
measurements	 were	 performed	 by	 a	 single	 observer	 using	 calipers	 measuring	
	 180	










sustained	 weight	 loss	 (72	 hrs.)	 of	 >20%,	 displayed	 adverse	 behaviour/physical	
condition	 or	 the	 planned	 number	 of	 days	 reached	 relevant	 to	 the	 experiment	
(detailed	in	section	3.2).	
	








Subject	 Right	shoulder	 Left	shoulder	 Notes	







Mouse	3	 200μl	injection	 200μl	injection	 Small	loss	left	
	
	















Mouse	2	 200μl	injection	 200μl	injection	 Small	loss	both	sides	
	
	
Mouse	3	 200μl	injection	 175μl	injection	 Bleed	on	injection	to	left,	
last	15μl	not	injected	
	












2	 tumours	 per	mouse)	 generated	 from	 SUIT-2	 tumour	matrix.	 The	 x-axis	 shows	
time	from	injection	of	cells	in	days,	the	y-axis	shows	the	tumour	volumes	in	mm3.		















































































































































Figure	 5.3	 A	 graph	 showing	 the	mean	 tumour	 growth	 of	 all	 tumours	 generated	
from	Miapaca-2		and	SUIT-2	tumour	matrix	injections.		The	x-axis	shows	time	from	
injection	 of	 cells	 in	 days,	 the	 y-axis	 shows	 tumour	 volume	 in	 mm3.	 The	 graph	
shows	 exponential	 tumour	 growth	 demonstrated	 by	 both	 tumour	 cell	 lines	 and	








height	 compared	 to	 miapaca	 tumours.	 	 This	 allowed	 earlier	 detection	 and	
mesurements	 to	 be	 performed	 at	 6-7	 days	 post	 injection.	 	 At	 the	 later	 stages	 of	
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	 186	
effected	 tumour	 measurements.	 	 In	 the	 SUIT-2	 group	 2	 animals	 needed	 to	 be	
sacrificed	owing	to	 this	phenomenon	 leading	to	 tumour	ulceration.	 	On	dissection	




Miapaca-2	 tumours	 grew	 in	 a	 flatter	 more	 nodular	 manner	 compared	 to	 SUIT-2	
tumours.		Each	tumour	was	composed	of	multiple	smaller	growths	that	were	firmily	
adhered	to	each	other	as	shown	in	figure	5.4,	slide	B.		Some	nodules	grew	at	a	small	





























Figure	 5.5	A	 graph	 showing	ex	 vivo	 correlation	of	 tumour	 volume	and	mass	 (16	
tumours	 total,	 8	 mice	 with	 2	 tumours	 per	 animal).	 The	 x-axis	 shows	 tumour	























































































ex	vivo	 (16	 tumours	 total,	 8	mice	with	2	 tumours	per	animal).	 The	x-axis	 shows	






























































































variables.	 	 The	 ex	 vivo	measurements	 of	 tumour	 volume	 correlated	with	 tumour	

























































































measurements	 performed	 and	 the	 ex	 vivo	 measurements	 obtained.	 The	
relationship	between	mass	and	volume,	although	significant,	was	weak.	 Indicating	
the	 heterogeneity	 of	 the	 tumours,	 but	 this	 does	 not	 detract	 from	 validity	 of	 the	
caliper	 measurements,	 which	 on	 this	 basis	 can	 be	 considered	 to	 be	 a	 justified	
measure	 of	 the	 expansion	 of	 the	 tumour	 (albeit	 not	 the	 only	 way	 this	 could	 be	






















Figure	 5.8	 A	 graph	 showing	 gemcitabine	 tolerability:	 the	 x-axis	 shows	 time	 of	
experiment	 in	 days,	 the	 y-axis	 shows	 mouse	 weight	 in	 grams.	 	 The	 crosses	
represent	a	dose	of	gemcitabine.	 	Lines	of	best	fit	were	produced	with	a	2-point	
































or	 if	 they	 experienced	 significant	 side	 effects.	 	 	 One	 animal	 died	 on	 day	 6	 of	









Figure	 5.9	 A	 graph	 showing	 AT7519	 tolerability:	 The	 x-axis	 shows	 time	 of	
experiment	 in	 days,	 the	 y-axis	 shows	 mouse	 weight	 in	 grams.	 	 The	 crosses	
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 



































































































AT7519! 0.29! 6! 0.045!
Gem! 0.445! 6! 0.038!
Vehicle! 0.162! 6! 0.502!
Figure 4: Mean difference in growth coefficients 











Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 





















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
!!!!
Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!











   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 








Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
!!
 Isobolar analysis of AT7519 combined 























Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 




































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
!
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Vehicle! 0.05! 6! T! 0.9991! 0.9906!
Gem! 0.162! 6! 0.0198! T! 0.1477!
AT7519! 0.114! 6! 0.029! 0.9374! T!
AT7519!+!Gem! 0.249! 6! 0.0041! 0.0611! 0.0173!
Figure 6:  Mean difference in 































Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 





























Thomas A1, Shaw E1, Ghaneh P1, Greenhalf W1, Costello E1, Dejani K1, Davies M1, Lyons J2, Sibson R1, Neoptolemos JP1 
! ! ! !1Department!of!Molecular!and!Clinical!Cancer!Medicine,!Ins7tute!of!Transla7onal!Medicine,!University!of!Liverpool!
! ! ! !2!Astex!Therapeu7cs,!Cambridge! ! ! ! ! ! ! ! !!!!!!!!!!!!!!!!!email: ajthomas@liv.ac.uk 
ASSESSMENT OF THE CDK INHIBI OR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanc d disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabin ,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT 519 is a selective CDK inhibito  providin  pot nt in ibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 





























































































AT7519! 0.29! 6! 0.045!
Gem! 0.445! 6! 0.038!
Vehicle! 0.162! 6! 0.502!
Figure 4: Mean difference in growth coefficients 











Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 





















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
!!!!
Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!











   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase follo ing 








Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
!!
 Isobolar analysis of AT7519 combined 























Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or ortality 
!
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
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•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after tr atment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth comp red with vehicle 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 





















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
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AT7519 as single agents and vehicle control 
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Figure 7: Anti-proliferative activity of 
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   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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 Isobolar analysis of AT7519 combined 























Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 




































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 









































The	 tolerability	 of	 AT13387	 was	 established	 in	 3	 non-tumour	 bearing	mice.	 	 The	
dose	 used	 was	 80mg/kg	 once	 per	 week	 based	 on	 the	 experiments	 of	 Astexs	
pharmaceuticals	in	other	in	vivo	solid	organ	malignancy	studies.	The	total	treatment	
time	 was	 14	 days.	 	 Animal	 sacrifice	 was	 performed	 after	 the	 14	 day	 treatment	
period	 or	 sooner	 if	 animals	 lost	 weight	 of	 >20%	 sustained	 over	 72	 hours,	 or	
experienced	significant	side	effects.				
There	was	no	significant	weight	loss	or	adverse	events	experienced	with	this	dosing	







Figure	 5.10	 A	 graph	 showing	 AT13387	 tolerability:	 the	 x-axis	 shows	 time	 of	
experiment	 in	 days,	 the	 y-axis	 shows	 mouse	 weight	 in	 grams.	 	 The	 crosses	




AT13387	 was	 well	 tolerated	 at	 80mg/kg	 once	 per	 week	 in	 non-tumour	 bearing	
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
REFERENCES
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.









AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
Suit-2GR  Control 



























Time from injection of cells (days)
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efficacy	 experiments	 with	 gemcitabine	 were	 performed	 in	 tumour	 bearing	 mice	
using	 the	 tolerated	 dose	 of	 100mg/kg	 twice	 a	week.	 Treatment	was	 commenced	
once	palpable	and	measurable	 tumours	were	established	and	 tumours	were	 then	
measured	 3	 times	 per	 week.	 	 Each	 mouse	 was	 inoculated	 with	 one	 shoulder	
tumour.	Daily	weights	and	observations	were	performed.		Treatment	was	continued	















Figure	 5.11	 A	 graph	 showing	 the	 tumour	 volume	 for	 6	 mice	 treated	 with	




Figure	 5.12	A	 graph	 showing	 the	 tumour	 volume	 for	 6	mice	 treated	with	 saline	
control	7.5mg/kg	BD	for	5	of	7	days	per	week	for	3	weeks.	The	x-axis	shows	days	







































































As	 observed	 tumour	 growth	 occurs	 in	 an	 exponential	 manner	 therefore	 a	 log	



































growth	observed	before	 and	after	 treatment.	 	 This	 further	 exemplified	 any	effect	
the	agent	had	as	complete	tumour	regression	was	not	observed.	
	
During	 the	 single	 agent	 efficacy	 study,	 gemcitabine	 significantly	 reduced	 the	
























































Figure	 5.15	 A	 graph	 showing	 the	 tumour	 volume	 of	 a	 mouse	 treated	 with	









































for	 the	 fall	 in	mean	 tumour	 volume	 rather	 than	 treatment	 exemplified	 in	 figures	
5.12	and	5.13).	
	
Because	 of	 the	 weight	 loss	 observed	 in	 non-tumour	 bearing	 animals	 in	 previous	
tolerability	 experiments	 and	 the	 weight	 loss	 observed	 in	 this	 first	 efficacy	
experiment,	 two	 reduced	 dosing	 regimens	 were	 tested	 in	 order	 to	 find	 a	
moderately	efficacious	dosing	regimen	to	progress	to	combination	studies.	
	






















Figure	 5.16	 A	 graph	 showing	 the	 tumour	 volume	 of	 a	 mouse	 treated	 with	
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   Before vehicle control 
 
   After vehicle control 
 














Table	 5.6	 A	 table	 of	 the	 log	 regression	 analysis	 coefficients	 for	 groups	 3	 and	 4	
(gemcitabine	 50mg/kg	 twice	 weekly	 versus	 vehicle	 control	 saline	 respectively)	
mean	difference	 after	 treatment	 for	 each	 group	with	p	 values	 of	 significance	 in	
difference.		
	







Gemcitabine	was	efficacious	 in	 this	mouse	model	 in	 reducing	exponential	 tumour	
growth	 when	 compared	 to	 saline	 control	 (p=0.0198).	 	 The	 initial	 dosing	 of	
gemcitabine	at	100mg/kg	twice	weekly	produced	unacceptable	adverse	effects	so	a	





AT7519	 was	 based	 on	 the	 experience	 of	 Astex	 pharmaceuticals	 in	 previous	
xenograph	models	 they	 had	 employed	 in	 testing	 other	 solid	 organ	 tumour	 types.		
From	tolerability	experiments	performed	it	was	confirmed	the	dosing	regime	would	
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•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT75 9 as a single agent showed 
a sig ficant r duction in tumour growth compared with vehicle 
control 

























































































AT7519! 0.29! 6! 0.045!
Gem! 0.445! 6! 0.038!
Vehicle! 0.162! 6! 0.502!
Figure 4: Mean difference in growth coefficients 











Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 



















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!











   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 








Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
!!
 Isobolar analysis of AT7519 combined 






















Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
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Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft exp riments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 1: Individual m ce weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 



















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
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agent and in combination with 
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significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
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Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
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•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT75 9 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 4: Mean difference in growth coefficients 











Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 



















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
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lines with  IC50 values from 0.2– 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
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The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 










































































In	 this	 xenograft	model	 of	 pancreatic	 cancer	 AT7519	 as	 a	 single	 agent	 showed	 a	




The	 efficacy	 of	 AT13387	 as	 a	 single	 agent	 was	 tested	 in	 this	 pancreatic	 cancer	
xenograft	model.		AT13387	was	dosed	as	per	the	tolerated	dosing	regimen	tested	at	
80mg/kg	 once	 weekly	 in	 BALB-c	 nude	 tumour	 bearing	 mice.	 	 Treatment	 was	
commenced	 on	 day	 13	 once	 palpable	 and	measurable	 tumours	were	 established	
and	tumours	were	then	measured	3	times	per	week.	 	Each	mouse	was	 inoculated	






























Inhibition of tumour growth in a pancreatic cancer xenograft model by 
AT13387, a novel Hsp90 inhibitor.
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
REFERENCES
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.









AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
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treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
r gression analysis was used to fit a curve to data points
before treatment and ove the first 10 days of treat ent
and ass gn coefficients. Treatment groups were compared
























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
sh wn circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.









AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
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P<0.001).
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• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
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• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
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AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can im rove inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
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Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
r gression analysis was used to fit a curve to data points
before treatment and ove the first 10 days of treat ent
and ass gn coefficients. Treatment groups were compared
























• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of


























Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
sh wn circled in red. Adapted from
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After	 all	 single	 agents	 had	 been	 investigated	 for	 tolerability	 and	 efficacy	
combination	studies	were	undertaken.	 	Any	agent	that	would	potentially	be	taken	
forward	 into	 human	 trials	 would	 be	 trial	 in	 combination	 with	 the	 current	 gold	





exploring	 the	 efficacy	 of	 this	 combination.	 	 The	 dose	 of	 AT7519	 remained	 at	
7.5mg/kg	 twice	a	day	 for	5	days	per	week	as	 this	had	proved	 to	be	 tolerable	and	
efficacious	 in	previous	studies.	 	The	dose	of	gemcitabine	used	was	50mg/kg	twice	
weekly	 as	 a	 moderately	 efficaous	 dose	 that	 was	 well	 tolerated	 in	 single	 agent	
studies	 (see	 table	 5.13).	 	 The	 tolerability	 study	 was	 performed	 in	 non	 tumour	
bearing	mice	 for	 a	 total	 period	of	 2	weeks	 treatment	with	3	mice.	 	Daily	weights	


















Figure	 5.22	 A	 graph	 showing	 AT7519	 and	 gemcitabine	 combination	 tolerability:	
the	 x-axis	 shows	 time	of	 experiment	 in	days,	 the	 y-axis	 shows	mouse	weight	 in	







































Figure	 5.23	 A	 graph	 showing	 AT7519	 and	 gemcitabine	 combination	 tolerability	
exemplified	 by	 percentage	weight	 loss:	 the	 x-axis	 shows	 time	 of	 experiment	 in	







































































The	 combination	 of	 AT13387	 and	 Gemcitabine	 was	 assessed	 prior	 to	 testing	
combination	efficacy	of	these	agents.		3	non	tumour	bearing	mice	were	dosed	for	a	
total	of	2	weeks.		The	dosing	of	each	agent	was	based	on	previous	tolerability	and	
efficacy	 studies	 on	 these	 as	 single	 agents.	 AT13387	 was	 dosed	 at	 80mg/kg	 once	
weekly	 (Tuesday)	 and	 gemcitabine	 50mg/kg	 twice	 weekly	 (Monday	 and	 Friday)	



















































Figure	 5.25	A	 graph	 showing	AT13387	 and	 gemcitabine	 combination	 tolerability	
[1]	exemplified	by	percentage	weight	loss:	the	x-axis	shows	time	of	experiment	in	
































































Figure	 5.26	A	 graph	 showing	AT13387	 and	 gemcitabine	 combination	 tolerability	
for	mouse	1:	the	x-axis	shows	time	of	experiment	in	days,	the	y-axis	shows	mouse	




Figure	 5.27	A	 graph	 showing	AT13387	 and	 gemcitabine	 combination	 tolerability	
for	mouse	2:	the	x-axis	shows	time	of	experiment	in	days,	the	y-axis	shows	mouse	






















































During	 this	 study	 significant	 weight	 loss	 was	 observed	 that	 necessitated	 missing	




The	 combination	 of	 AT13387	 and	 Gemcitabine	 at	 the	 doses	 tested	 was	 not	 well	
tolerated	owing	to	weight	loss	that	necessitated	missing	doses.		In	light	of	this	fact	




























The	 modifications	 to	 the	 dosing	 regime	 for	 AT13387	 and	 Gemcitabine	 were	
considered.		Owing	to	the	fact	that	issues	around	weight	loss	were	mostly	observed	
with	 the	 use	 of	 gemcitabine	 in	 previous	 experiments	 the	 decision	 was	 taken	 to	
reduce	the	dose	of	gemcitabine	to	25mg/kg.		3	non	tumour	bearing	nude	mice	were	
















Figure	 5.29	 A	 graph	 showing	 AT13387	 and	 gemcitabine	 combination	
































Figure	 5.30	A	 graph	 showing	AT13387	 and	 gemcitabine	 combination	 tolerability	
[2]	exemplified	by	percentage	weight	loss:	the	x-axis	shows	time	of	experiment	in	
days,	 the	 y-axis	 shows	 percentage	 weight	 loss	 in	 each	mouse.	 	 Orange	 crosses	
represent	a	dose	of	AT1387,	black	crosses	represents	a	dose	of	gemcitabine.		
	
In	 this	 study	 the	 combination	 of	 AT13387	 and	 gemcitabine	 was	 better	 tolerated	




The	 combination	 of	 AT13387	 at	 80mg/kg	 once	weekly	 and	Gemcitabine	 25mg/kg	
twice	 weekly	 was	 better	 tolerated	 than	 previous	 dosing	 schedules	 tested.	 	 This	




























































From	 combination	 tolerability	 studies	 and	 single	 agent	 efficacy	 studies	 this	
experiment	was	undertaken	with	the	aim	to	find	the	efficacious	dosing	schedule	for	





13	 days	 after	 tumours	 were	 injected	 subcutaneously	 and	were	 all	 measurable	 in	
order	 to	enable	volume	calculations.	 	 Treatment	was	carried	out	 for	3	weeks	and	
the	experimental	endpoints	as	previously	described	adverse	events	or	to	the	end	of	








Group	 Agent	 Dose	 Number	of	animals	
1	 Vehicle	1	(saline)	 50mg/kg	twice	weekly	 6	
Vehicle	2	(saline)	 7.5mg/kg	BD	(1-5	days)	
2	 Gemcitabine	 50mg/kg	twice	weekly	 6	
Vehicle	2	(saline)	 7.5mg/kg	BD	(1-5	days)	
3	 Vehicle	1	(saline)	 50mg/kg	twice	weekly	 6	
AT7519	 7.5mg/kg	BD	(1-5	days)	
4	 Gemcitabine	 50mg/kg	twice	weekly	 6	
AT7519	 7.5mg/kg	BD	(1-5	days)	




growth	 was	 observed	 that	 was	 superior	 to	 vehicle	 control	 (p=0.0041)	 as	 well	 as	
























0.05	 6	 -	 0.9991	 0.9906	
Gemcitabine	
	
0.162	 6	 0.0198	 -	 0.1477	
AT7519	
	
0.114	 6	 0.029	 0.9374	 -	
AT7519	+	
Gemcitabine	
0.249	 6	 0.0041	 0.0611	 0.0173	
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 





























































































AT7519! 0.29! 6! 0.045!
Gem! 0.445! 6! 0.038!
Vehicle! 0.162! 6! 0.502!
Figure 4: Mean difference in growth coefficients 











Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 



















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single age ts a d vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
!!!!
Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!











   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 








Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
!!
 Isobolar analysis of AT7519 combined 























Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
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Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 



















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greate  for the 
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MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 4: Mean difference in growth coefficients 











Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 





















































Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
!!!!
Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!











   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 








Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
!!
 Isobolar analysis of AT7519 combined 























Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 


































Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greate  for the 





























Before AT7519 + gemcitabine 
 











In	 this	 xenograft	 model	 of	 pancreatic	 cancer	 AT7519	 combined	 with	 gemcitabine	










The	 dosing	 of	 AT13387	 780mg/kg	 once	 weekly	 and	 25mg/kg	 gemcitabine	 twice	




(previously	 Monday	 and	 Friday)	 and	 AT13387	 was	 administered	 on	 Tuesdays	 as	















































































Following	promising	 single	agent	 results	 supporting	a	 reduction	 in	 tumour	growth	
following	AT13387	treatment	the	compound	was	tested	in	vivo	in	combination	with	
gemcitabine.	 Once	 weekly	 dosing	 of	 AT13387	 at	 80mg/kg	 combined	 with	 twice-
weekly	dosing	of	gemcitabine	at	25mg/kg	was	tolerated	 in	vivo.	This	schedule	was	
selected	 as	 higher	 doses	 of	 gemcitabine	 combined	 with	 AT13387	 resulted	 in	




































Figure	 5.35	A	 graph	 showing	 the	 relative	 tumour	 volumes	 in	mice	 treated	with	
Saline	 vehicle	 control,	 Gemcitabine	 alone,	 AT13387	 alone	 and	 Gemcitabine	 +	
AT13387.	Treatment	 commenced	on	day	13.	The	x-axis	 shows	 time	 in	days	 from	
injection	of	cells	and	the	y-axis	shows	the	relative	tumour	volumes.		
	
Adverse	 events	 were	 encountered	 during	 this	 experiment.	 	 Three	 animals	 died	
unexpectedly	and	one	was	sacrificed	owing	to	ill	health	(2	had	combination	therapy	
and	 2	 single	 agent	AT13387).	 	Necropsy	was	 performed	on	 the	 animals	 that	 died	
unexpectedly	showed	ascites	and	dilated	bowel	in	all	3	animals.	
During	 the	 experiments	 3	 doses	 of	 gemcitabine	 and	 one	 dose	 of	 AT13387	 was	


































AT13387	 and	 gemcitabine	 reduced	 tumour	 growth	 significantly	 compared	 to	
controls	but	was	no	better	than	single	agents	in	slowing	this	growth.		Furthermore	






















offer	 benefits	 for	 	 pancreatic	 cancer	 patients,	 	 this	 is	 a	 complex	 disease	 with	
multiple	 genetic	 and	 protein	 defects.	 	 Targeting	 pathways	 such	 as	 that	 of	 CDK	







cells	 lines	 was	 established.	 	 AT7519	 demonstrated	 ability	 to	 induce	 growth	
inhibition	across	a	range	of	pancreatic	cancer	cell	 lines.	 	The	effect	of	AT7519	was	
explored	in	standard	lines	and	an	in-house	developed	gemcitabine	resistant	line.		In	
light	 of	 the	 known	 chemoresistance	 demonstrated	 to	 gemcitabine	 the	 effects	 of	
novel	 agents	 in	 this	 cell	 line	 were	 important.	 	 It	 was	 observed	 that	 AT7519	
demonstrated	ability	to	 inhibit	growth	 in	this	resistant	 line	furthermore	 looking	at	
	 239	





Gemcitabine	 resistance	 is	 an	 important	 issue	 to	 overcome	 in	 PDAC	 and	 the	
mechanisms	are	being	uncovered	as	in	vitro	and	in	vivo	study	is	taken	into	this	area.		
The	 action	 of	 gemcitabine	 is	 dependent	 on	 its	 uptake	 into	 cells	 via	 transporters	
including	 hENT1	 and	 2	 (human	 equilibrative	 nucleoside	 transporter	 1	 and	 2)	 and	
hCNT1	 and	 3	 (human	 concentrative	 nucleoside	 transporters	 1	 and	 3)	 then	
intracellular	metabolism	via	dCK	 (enzyme	deoxycytidine	kinase)	 leads	 to	an	active	




reach	 the	 target	 cells	 and	 the	 cellular	 events	 leading	 to	 gemcitabine	metabolism	
including	the	levels	of	transporters	and	enzymes	aforementioned	(Mackey,	Mani	et	





the	 same	 cellular	 blocks	 to	 its	 activity	 and	 if	 anything	 was	more	 effective	 in	 the	
gemcitabine	resistant	line,	the	mechanisms	for	this	remain	unknown	but	this	offers	
promise	 for	 AT7519	 as	 a	 potential	 second	 line	 agent	 in	 patients	 who	 have	 not	
responded	 to	 gemcitabine	 therapy	 or	 AT7519	 to	 be	 given	 in	 combination	 with	
gemcitabine	to	attempt	to	overcome	the	resistance	currently	seen.				In	previous	in	







a	marked	 reduction	of	 cells	 in	G0/1	 and	 S	phases.	 	 	 	 Its	 activity	 observed	here	 in	
pancreatic	cancer	cell	lines	is	consistent	with	previous	investigations	of	this	agent	in	
other	 solid	 organ	 tumour	 types	 including	 colorectal	models	 (Squires,	 Feltell	 et	 al.	
2009).	 It	 is	 also	 in	 line	 with	 inhibition	 of	 substrates	 of	 CDKs	 1	 and	 2,	 supporting	
AT7519	as	a	potent	inhibitor	of	these	CDKs(Nyberg,	Michelson	et	al.	2002;	Donzelli	










The	 S	 phase	 accumulation	 observed	 was	 more	 marked	 using	 this	 combination	
compared	 to	 the	 actions	 of	 gemcitabine	 alone	 as	 a	 single	 agent.	 	 This	 raises	 two	
possibilities;	 AT7519	 may	 be	 enhancing	 the	 cell	 cycle	 effects	 of	 gemcitabine	 or	
exerting	effects	on	the	S	phase	checkpoint.	
	
From	 literature	 evidence	 the	 S	 phase	 checkpoint	 is	 in	 part	 dependent	 on	 CDK	 2	
activity,	therefore	AT7519	may	be	exerting	its	effects	on	CDK2	activity	more	notably	
in	 these	 cells	 that	 have	 been	 arrested	 by	 gemcitabine	 activity	 (Bartek	 and	 Lukas	







noted	 in	vitro	 the	 increased	caspase-3	activity	was	seen	between	16	and	48	hours	




cell	cycle	that	AT7519	needs	to	be	present	 in	order	to	 induce	apoptosis.	 	Previous	
investigation	of	AT7519	in	Myeloma	cell	lines	also	noted	apoptosis	between	12	and	




The	 importance	 of	 scheduling	 AT7519	 with	 gemcitabine	 to	 allow	 both	 agents	 to	
take	maximal	effect	was	further	demonstrated	by	isobolar	analysis.		When	AT7519	




have	 its	effect,	when	cells	are	 treated	with	AT7519	the	G2/M	block	prevents	 this.		
Interestingly	this	same	antagonism	was	not	indicated	in	the	cell	cycle	analysis	where	
gemcitabine	 still	 seemed	 to	be	having	an	effect,	 in	 fact	 the	S	phase	accumulation	
noted	was	more	marked	when	the	drugs	were	combined.	In	light	of	the	antagonism	
observed	 sequential	 addition	 of	 the	 agents	was	 tested.	 	 The	 results	 showed	 that	











in	the	 literature	 in	the	pre	clinical	setting.	 	Flavopiridol	 is	a	selective	CDK	 inhibitor	
with	 a	 profile	 similar	 to	 that	 of	 AT7519	 (inhibition	 of	 CDK	 1,2,4	 and	 7)	 and	 has	
demonstrated	activity	in	a	number	of	tumour	types	in	vitro	and	in	xenograft	models	
(Bible	 and	 Kaufmann	 1996;	 Carlson,	 Dubay	 et	 al.	 1996).	 	 Its	 combination	 therapy	
with	 gemcitabine	 and	 the	 importance	of	 drug	 sequencing	was	 investigated	 in	 the	
pre-clinical	setting.		It	was	noted	that	gemcitabine	followed	by	flavopiridol	resulted	
in	 the	maximum	 antitumour	 effect	 and	 the	 pro	 apoptotic	 effects	 of	 gemcitabine	
were	enhanced.		The	reverse	combination	did	not	show	any	superiority	over	either	
agent	 alone	 (Jung,	Motwani	 et	 al.	 2001).	 	 On	 the	 basis	 of	 this	 clinical	 trails	 have	




When	 downstream	 markers	 were	 investigated	 the	 effects	 of	 AT7519	 on	 key	




was	 given	 in	 combination	 with	 Gemcitabine	 this	 decrease	 was	 less	 marked	 and	
when	gemcitabine	was	given	prior	to	AT7519	no	effect	on	cdc2	levels	were	noted.		
This	 can	 be	 explained	 by	 the	 effect	 of	 gemcitabine	 causing	 an	 S	 phase	 arrest,	
supported	 by	 the	 cell	 cycle	 activity	 of	 AT7519	 in	 combination	 with	 gemcitabine	





potential	 synergy	with	 gemcitabine	 that	 is	 having	 effects	 at	 this	 point	 in	 the	 cell	
cycle.	 	 This	was	also	observed	 in	phospho	pp1-a	 	 and	phospho	NPM	proving	 that	
AT7519	 has	 an	 effect	 on	 CDK	 inhibition	 as	 all	 of	 these	 proteins	 have	
phosphorylation	that	 is	catalysed	by	CDKs.	 	The	decreased	 levels	of	Phospho	NPM	
were	also	investigated	when	cells	were	treated	with	the	combination	of	AT7519	and	
gemcitabine	and	 this	effect	was	again	present	by	more	marked	with	 combination	
treatment.	 	 This	 perhaps	 is	 explained	 by	 the	 fact	 that	 NPM	 is	 a	 nuclear	 residing	
protein,	 in	 the	 nucleolus	 or	 cytoplasm	 of	 the	 nucleus	 and	 perhaps	 the	 effects	 of	
gemcitabine	and	its	transport	within	the	nucleus	inhibit	its	phosphorylation	further.				
	
In	 targeting	 multiple	 pathways	 general	 CDK	 inhibitors	 such	 as	 AT7519	 provide	 a	
promising	 therapeutic	 option	 excerpting	 both	 direct	 cell	 cycle	 and	 transcription	






The	 observations	 on	 downstream	markers	 showed	AT7519	 is	 having	 an	 effect	 on	
the	 cell	 cycle	 although	 these	 were	 not	 significant	 enough	 at	 the	 expected	 IC50	






In	a	murine	model	AT7519	was	 investigated	as	a	 single	agent	and	 in	 combination	




There	 was	 a	 significant	 reduction	 in	 tumour	 growth	 compared	 to	 control.	 The	
effects	 of	 AT7519	 on	 tumour	 xenografts	 in	 colorectal	 cell	 lines	 showed	 more	
marked	evidence	of	apoptosis	where	regression	of	tumours	was	noted	with	AT7519	
treatment(Squires,	Feltell	et	al.	2009),	the	effects	observed	in	this	model	were	more	
in	 line	 with	 the	 current	 evidence	 for	 CDK	 inhibitors	 in	 Xenograft	 models	 where	
reduction	in	growth	with	no	noted	regressions	have	been	noted	(Patel,	Senderowicz	
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et	 al.	 1998;	 McClue,	 Blake	 et	 al.	 2002).	 More	 recently	 a	 novel	 CDK	 inhibitor	
Dinaciclib	was	 demonstrated	 to	 inhibit	 pancreatic	 cancer	 progression	 in	 a	murine	






to	 human	 trials,	 therefore	 proving	 compatibility	 or	 synergy	 with	 the	 standard	
therapy	would	be	mandatory.		In	this	murine	model	the	combination	of	AT7519	and	
Gemcitabine	 was	 well	 tolerated	 and	 proved	 to	 be	 efficacious.	 	 The	 combination	
treated	mice	had	a	significant	reduction	in	tumour	growth	compared	to	control	and	
AT7519	as	a	 single	agent,	 there	was	also	a	 trend	 for	 superiority	over	gemcitabine	
alone	though	this	was	not	quite	statistically	significant	(	p	=	0.0611).	 	 	 	The	results	
gained	here	are	similar	to	that	of	other	work	done	on	CDK	inhibition	in	pancreatic	
cancer	 models.	 	 P276	 (a	 CDK	 4	 inhibitor)	 was	 tested	 in	 combination	 with	













current	 therapeutic	 results.	 	 The	 inability	 of	 gemcitabine	 to	 induce	 apoptosis	 in	 a	
large	number	of	pancreatic	 tumours	 is	multifactorial	but	 the	 intimate	 relationship	
between	the	cell	cycle	and	programmed	cell	death	cannot	be	dismissed	for	example	








points	 in	 the	 cell	 cycle	 because	 of	 the	 loss	 of	 integrity	 of	 these	 checkpoints.		
Targeting	 multiple	 CDKs	 would	 recapture	 these	 stop	 check	 points	 that	 limit	 the	
tumour	cells	ability	to	pass	through	the	cell	cycle	and	may	then	allow	induction	of	
apoptosis.	 	 	 This	 would	 obviously	 be	more	 assured	 if	multiple	 targets	 were	 used	
rather	then	a	single	target	and	potentially	single	point	within	the	cell	cycle.		This	far	
most	 of	 the	 combined	 studies	 of	 chemotherapeutics	 and	CDK	 inhibitors	 has	 used	
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pan-CDK	 inhibitors	 such	 as	 flavopiridol	 although	 focus	 have	 shifted	 toward	
developing	compounds	that	are	more	potent	and	selective	in	their	action	(Dickson	
and	 Schwartz	 2009).	 	 The	 combination	 of	 chemotherpaturitcs	 and	 CDK	 inhibitors	
that	 have	 an	 effect	 on	 CDK1	 and	 2	 (like	 AT7519)	 may	 be	 the	 most	 desirable	
combinations	 owing	 to	 the	 synergistic	 effects	 noted	 in	 the	 literature	 with	 DNA	
damage	 causing	 chemotherapeutic	 agents	 (Ira,	 Pellicioli	 et	 al.	 2004;	 Maude	 and	
Enders	2005).		As	the	knowledge	on	the	genetic	basis	of	pancreatic	adenocarcinoma	
becomes	clearer	this	question	will	be	more	readily	answered,	certainly	the	effects	
demonstrated	 by	 AT7519	 offer	 promise	 and	 suggest	 that	 at	 least	 partly	 this	
selective	CDK	inhibitor	offers	a	useful	therapeutic	option	as	an	adjunct	to	standard	
therapy.	 	The	 information	to	date	on	CDK	 inhibitors	support	the	notion	that	using	




combination	 with	 gemcitabine	 to	 improve	 therapy	 in	 pancreatic	 cancer	 and	
overcome	 some	of	 the	 cell	 cycle	proteins	 involved	 in	 the	 resistance	of	 pancreatic	


















In	 this	 study	 the	effects	of	AT13387	were	examined	 in	vitro	 and	 in	vivo	both	as	a	
single	 agent	 and	 in	 combination	 with	 gemcitabine.	 	 AT13387	 induced	 growth	
inhibition	across	a	range	of	pancreatic	cancer	cell	lines	at	the	nanomolar	level.		The	
IC50	 values	 obtained	 in	 this	 study	 are	 comparable	 to	 the	 values	 that	 have	 been	















occurred.	 	 This	 suggested	 AT13387	 was	 having	 a	 cytostatic	 rather	 than	 cytotoxic	
effect.		This	effect	of	AT13387	is	notably	different	to	other	HSP90	inhibitors	but	may	
not	necessarily	be	a	disadvantage	when	used	in	the	setting	of	combination	therapy.		
The	 ability	 of	 AT13387	 to	 leave	 the	 cell	 in	 a	 quiescent	 state	may	 then	 allow	 the	




The	 cell	 cycle	 effects	 of	 AT13387	were	 demonstrated	with	 an	 increase	 of	 cells	 in	
G0/G1	and	G2/M	phases	after	 treatment.	 	 In	combination	with	gemcitabine	 the	S	
phase	 accumulation	 of	 cells	 exhibited	 by	 gemcitabine	 treatment	 alone	 was	
documented.	 	 The	 multiple	 pathways	 and	 proteins	 targeted	 by	 HSP90	 inhibition	
may	 account	 for	 there	 being	 no	 specific	 point	 in	 the	 cell	 cycle	 where	 cells	
accumulate.	 	The	encouraging	data	 from	this	cell	cycle	analysis	 is	 that	despite	 the	
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When	 apoptosis	 was	 investigated	 it	 was	 demonstrated	 beyond	 40	 hours	 after	
treatment	 with	 AT13387.	 	 AT13387	 does	 not	 appear	 to	 produce	 apoptosis	 at	 an	
early	 stage,	 this	 is	 converse	 to	 the	observations	with	other	HSP90	 inhibitors	 (Kim,	
Kang	et	al.	2003)	and	the	actions	of	AT13387	observed	in	other	tumour	lines	(astex	
pharmaceuticals,	 data	 not	 published).	 	 The	 fact	 that	 AT13387	 interferes	 with	
protein	folding	and	subsequent	cell	division	on	a	number	of	levels	may	suggest	that	
the	 ability	 to	 push	 the	 cell	 forward	 to	 apoptosis	 takes	 some	 time,	 perhaps	







or	geldanacycim	(Burkitt,	Magee	et	al.	2007).	 	 It	has	also	been	suggested	that	 the	
global	effect	of	HSP90	 inhibition	 to	potentiate	 the	action	of	other	agents	may	act	
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through	mechanisms	 quite	 distinct	 from	 those	 employed	when	 acting	 as	 a	 single	
agent.			
	
The	effects	of	combining	AT13387	and	gemcitabine	 in	vitro	 in	an	 isobolar	analysis	
did	 not	 yield	 any	 clear	 results	 in	 these	 experiments,	 though	 these	 combination	
studies	did	allow	some	observations.	 	There	was	a	trend	for	enhanced	AT13387	in	
the	 presence	 of	 gemcitabine	 and	 perhaps	 this	 is	 more	 striking	 as	 in	 these	
experiments	 AT13387	 did	 not	 reach	 its	 IC50	 as	 a	 single	 agent	 but	 did	 in	 the	
presence	 of	 gemcitabine.	 	 Gemcitabine	 acts	 on	 the	 cell	 in	 S	 phase	 causing	
irreversible	DNA	damage	but	as	suggested	previously	this	may	not	occur	on	the	first	
cell	 cycle	 that	 gemcitabine	 comes	 into	 contact	 with	 the	 cell,	 perhaps	 the	 initial	
insult	of	gemcitabine	treatment	makes	the	cells	more	vulnerable	to	the	actions	of		




AT13387	 induced	 inhibition	 of	 HSP90	 was	 evident	 from	 examination	 of	 client	
proteins.	 	 Both	 Akt	 and	 phospho	 Akt	 levels	 were	 reduced	 after	 treatment	 with	
AT13387,	this	effect	was	less	marked	when	cells	had	been	treated	with	gemcitabine	




that	 after	 gemcitabine	 treatment	 the	 effects	 were	 less	 prominent	 suggests	 cells	
were	already	sustaining	the	DNA	damaged	caused	by	gemcitabine	treatment	and	a	
lesser	effect	of	AT13387	was	noted.		The	same	effect	was	true	on	phospho	S6	when	





to	 inhibit	 cellular	 proliferation	more	 so	 in	 combination	 treatment	 (Martin-Liberal,	
Gil-Martin	et	al.	2014)	
	
Client	proteins	 involved	 in	the	 important	MAPK	cascade	were	also	examined	after	
treatment	with	AT13387.	Raf-1	levels	were	decreased	in	cells	treated	with	AT13387.	
This	 effect	 was	 enhanced	 with	 the	 combination	 treatment	 with	 gemcitabine.	 In	
addition	to	these	above	many	cell	cycle	regulatory	proteins	are	affected	by	HSP90	
inhibitors,	 including	 CDK4,	 and	 in	 this	 study	 CDK4	 levels	 were	 reduced	 following	
treatment	with	AT13387,	this	effect	was	more	marked	and	noted	at	lower	doses	of	






	Treatment	with	AT13387	 resulted	 in	 significant	up	 regulation	of	HSP70	both	as	 a	
single	agent	and	combined	with	gemcitabine,	as	a	co-chaperone	to	HSP90	inhibition	
this	is	in	line	with	actions	of	HSP90	inhibition	previously	recognized	in	the	literature.		
This	 effect	 was	 not	 inhibited	 by	 combination	 treatment	 or	 pre	 treatment	 with	
gemcitabine.	 	 	 	 The	 overexpression	 of	 HSP70	 relates	 to	 the	 heat	 shock	 response	
induced	 y	 this	 inhibitor	 and	 it	 is	 worth	 noting	 this	 could	 effect	 the	 agents	 anti-
cancer	 activity	 as	 overexpression	 of	 HSP70	 could	 induce	 pro-survival	 and	 anti-




The	 effects	 of	 AT13387	 as	 a	 single	 agent	 in	 a	 mouse	 xenograft	 model	 initially	
suggested	 potentially	 promising	 effects.	 	 The	 drug	 was	 well	 tolerated	 as	 a	 single	
agent	and	did	result	in	slowed	tumour	growth	compared	to	control	though	this	was	
not	 statistically	 significant.	 	When	 the	 agent	was	 combined	with	 gemcitabine	 the	
results	 were	 unfortunately	 less	 favorable.	 	 The	 combination	 of	 AT13387	 and	
gemcitabine	was	no	better	at	slowing	tumour	growth	than	either	agent	alone	and	




cell	 line	 xenograft	 model.	 	 After	 a	 single	 dose	 tumour	 half-life	 was	 65	 hours	
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compared	 to	 around	 4	 hours	 in	 plasma/blood	 (Graham,	 Curry	 et	 al.	 2012).	 	 The	
effects	 on	 downstream	 markers	 were	 prolonged	 compared	 to	 other	 HSP90	
inhibitors	 such	 as	 17-AAG.	 	 In	 this	 same	 model	 tumour	 growth	 was	 significantly	
reduced	compared	to	controls.	 	An	advantage	of	this	prolonged	tumour	half-life	 is	





Dose	 limiting	 toxicity	 in	 HSP90	 xenograft	 models	 and	 human	 studies	 has	 been	
previously	 noted,	 mostly	 relating	 to	 gastrointestinal	 and	 liver	 toxicity	 (Banerji,	
Walton	et	 al.	 2005;	 Sequist,	Gettinger	 et	 al.	 2010).	 	 It	 is	 not	 surprising	bearing	 in	
mind	 the	 mechanism	 of	 action	 of	 HSP90	 inhibitors	 that	 global	 effects	 are	 seen	
frequently.	 	 In	 this	model	AT13387	 as	 a	 s	 ingle	 agent	was	well	 tolerated	perhaps	
owing	to	the	prolonged	tumour	half-life	therefore	less	frequent	dosing	regime	that	
was	employed.	 	 	 	Although	dose	 limiting	toxicity	was	experienced	 in	this	model	 in	
combined	 treatment	 of	 AT13387	 and	 gemcitabine	 in	 phase	 I	 studies	 of	 AT13387	
alone	 these	 have	 not	 been	 encountered	 at	 the	 same	 dosing	 levels	 offering	
encouragement	 that	 in	 human	 trials	 the	 same	 issues	may	 not	 be	 encountered	 in	
combination	 therapy.	 	 Even	 at	 higher	 doses	 of	 AT13387	 in	 humans	 the	 toxicities	
encountered	 were	 grade	 1-2(Do,	 Speranza	 et	 al.	 2015).	 	 The	 fact	 remains	 that	





in	pancreatic	 xenograft	models	 alone	 (Moser,	 Lang	et	 al.	 2012)	or	 in	 combination	




xenograft	 model	 showed	 no	 improvement	 over	 either	 single	 agent	 alone.	
Unfortunately	 poor	 tolerability	 of	 the	 combined	 regime	 resulted	 in	 a	 reduce	
gemcitabine	dosage	to	that	initial	planned	for	combination	studies	which	may	have	
impacted	on	 the	efficacy	 in	 this	model.	 Each	agent	 alone	produced	 some	modest	
weight	 loss	but	 the	 combined	 therapy	 resulted	 in	an	additive	effect	 in	 relation	 to	
this	 side	 effect	 that	 impacted	 on	 dosing	 and	 survival	 in	 the	 model.	 	 Further	





This	 study	 sought	 to	 investigate	 AT13387	 in	 combination	 with	 the	 current	 gold	
standard	 treatment	 for	pancreatic	 cancer,	 gemcitabine.	Combined	 treatment	with	
gemcitabine	and	AT13387	apparently	resulted	in	no	greater	effect	than	either	single	






reduce	 raf-1	 protein	 levels	 further	 then	 the	 decrease	 seen	 with	 AT13387	 alone.	
Further	 investigation	 is	 required	 to	examine	 the	effects	on	other	members	of	 the	
pathway	 including	MEK.	These	data	suggest	a	potential	avenue	of	 investigation	of	
combining	 MEK	 inhibitors	 in	 this	 regime.	 There	 are	 a	 number	 of	 MEK	 inhibitors	
under	 investigation	 including	 a	 number	 of	 phase	 I/II	 clinical	 trials	 examining	MEK	
inhibitors	in	combination	with	gemcitabine	(Wong	2009;	Trujillo	2011).	
	
Although	 this	 data	 would	 not	 support	 adding	 AT13387	 to	 standard	 gemcitabine	
therapy,	 the	 continued	 activity	 of	 AT13887	 in	 the	 gemcitabine	 resistant	 Suit-2GR	
cells	indicates	that	this	agent	may	be	of	benefit	in	patients	who	have	not	responded	
to	gemcitabine	treatment	and	possibly	in	combination	with	other	alternative	agents	
that	 may	 enhance	 its	 activity	 such	 as	 MEK	 inhibitors.	 	 	 The	 fact	 remains	 that	
pancreatic	cancer	contains	multiple	molecular	aberrations	and	targeting	HSP90	and	









combination	 with	 standard	 therapy.	 	 	 Further	 investigation	 of	 this	 agent	 in	
combination	with	 cell	 lines	 that	 are	 resistant	 to	 gemcitabine	 therapy	may	 offer	 a	
sub	 group	 that	 would	 have	 an	 enhanced	 benefit	 from	 this	 agent,	 biomarker	


























combination	 with	 gemcitabine	 in	 vitro	 having	 anti-proliferative	 effects	 against	 a	
range	 of	 pancreatic	 cancer	 cell	 lines.	 	 In	 vivo	 AT7519	 demonstrated	 efficacy	 and	
tolerability	both	as	a	single	agent	and	in	combination	with	gemcitabine.		AT7519	is	a	
potential	agent	that	warrants	further	investigation	in	pancreatic	cancer	and	may	be	
beneficial	 in	 reducing	 the	 issues	 currently	 faced	 with	 chemoresistance	 standard	
therapies.			
	
HSP90	 is	 involved	 in	 the	 regulation	 of	many	 oncogenic	 proteins	 and	 its	 inhibition	
and	 the	 subsequent	 effects	 of	 multiple	 molecules	 and	 pathways	 is	 an	 attractive	
prospect	 in	 cancer	 therapy.	 	 This	 is	 particularly	 relevant	 to	 pancreatic	 cancer,	 as	
more	 is	understood	about	 the	cancer	biology	 the	complex	and	multiple	pathways	
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that	 are	 deranged,	 these	 need	 to	 be	 targeted	 in	 order	 to	 improve	 the	 poor	
outcomes	that	current	chemotherapeutics	provide.		
	
In	 this	 study	 AT13387,	 a	 novel	 HSP90	 inhibitor,	 showed	 activity	 in	 vitro	 against	
pancreatic	cancer	cell	lines	including	one	with	acquired	gemcitabine	resistance	and	
down	 stream	 effects	 consistent	 with	 HSP90	 inhibition	 were	 observed.	 	 In	 vivo	
AT13387	 slowed	 tumour	 growth	 as	 a	 single	 agent	 but	 performed	 poorly	 in	
combination	with	gemcitabine.	 	The	data	presented	does	not	support	the	addition	
of	At13387	to	current	gemcitabine	therapy	but	does	offer	some	possibilities	as	an	




pancreatic	 cancer	 continues	 to	pose	 a	 significant	 health	problem	and	 is	 in	 urgent	
need	 of	 new	 and	 novel	 therapies	 which	 offer	 better	 outcomes	 for	 the	 patients	
affected.	 	 	Combining	 treatments	 is	desirable	as	previously	discussed	with	current	
understanding	of	the	multiple	pathways	related	to	pancreatic	cancer.	 	 	Combining	
chemotherapeutic	 agents	 has	 been	 this	 far	 disappointing	 with	 no	 significant	
improvements	 in	overall	survival	but	 increased	toxicity.	 	 	More	research	is	needed	
on	 the	 reasons	 for	 resistance	 to	 existing	 therapies	 and	 further	 clinical	 trials	 on	
combinations	 of	 gemcitabine	 with	 agents	 that	 would	 target	 cells	 resistant	 to	
gemcitabine.	 	 Combining	 standard	 chemotherapeutic	 agents	with	 novel	 therapies	
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advances	 in	 many	 other	 cancers	 leading	 to	 improved	 survival	 the	 incidence	 and	
mortality	 rates	 for	 pancreatic	 cancer	 have	 not	 seen	 any	 significant	 improvement	
over	the	last	30	years	and	are	predicted	to	remain	static	in	Europe	in	2012(Malvezzi,	
Bertuccio	et	al.	2012).	
The	 basis	 of	 current	 therapies	 for	 PDAC	 involves	 targeting	 of	 DNA	 replication	 by	
inhibition	 of	 thymidylate	 synthase	 and	 incorporation	 of	 fluorouridine	 derivatives	
into	 nascent	 DNA	 strands.	 	 The	 agents	 that	 are	 used	 are	 5-FU,	 capcetabine	 and	
gemcitabine	and	also	have	an	effect	on	transcription	and	DNA	methylation.		These	
therapies	 are	 used	 in	 both	 the	 adjuvant	 and	 advanced	 disease	 setting	 based	 on	
previous	 trial	 evidence	 (Burris,	 Moore	 et	 al.	 1997;	 Neoptolemos,	 Stocken	 et	 al.	
2004;	Oettle,	Post	et	al.	2007;	Sultana,	Smith	et	al.	2007;	Neoptolemos,	Stocken	et	
al.	2010;	Conroy,	Desseigne	et	al.	2011).	Despite	the	demonstrated	survival	benefits	
recurrence	 rates	 in	 resected	 disease	 remain	 high	 and	 in	 all	 disease	 settings	 long-




targeting	 these	 areas	 that	 lead	 to	 resistance	 or	 targeting	 multiple	 pathways	 in	
combination	with	standard	therapy.	 	Jones	et	al	 identified	12	pathways	commonly	




of	 making	 significant	 differences	 to	 survival	 of	 patients.	 	 Genetic	 mutations	 that	
arise	 in	pancreatic	 cancer	often	have	effect	on	 crucial	 checkpoints	within	 the	 cell	
	 289	
cycle	and	CDK’s	being	pivotal	to	cell	cycle	regulation	could	offer	another	target	for	
inhibition	 in	 pancreatic	 cancer.	 CDK	 inhibition	 could	 offer	 future	 promise	 for	
therapy	in	PDAC.	




of	 CDK’s	 and	 cyclins	 are	 frequently	 deranged	 in	 cancer.	 	 This	 may	 be	 due	 to	






D1	or	deletion	of	p16INK4A	activates	 the	pRb	pathway	 in	 this	manner.	 	P53	 is	an	
essential	 regulator	 of	 the	G1	 checkpoint	 and	 arrests	 growth	 through	 induction	of	
p21	and	G2	arrest	by	promoting	transcription	of	GADD45	that	inhibits	cyclin	B-CDK1	
activation.	
The	role	of	aberrant	CDK	activity	and	potential	 inhibition	has	been	 investigated	 in	
many	human	cancers.	 	Novel	CDK	 inhibitors	have	also	been	 investigated	 in	PDAC.		
Brasca	 et	 al	 reported	 on	 a	 novel	 CDK	 inhibitor	 PHA-793887	 and	 its	 effects	 in	 a	
xenograft	model	of	pancreatic	cancer	using	the	tumour	line	Bx-PC3.		The	agent	was	
well	 tolerated	 and	 resulted	 in	 significant	 tumour	 growth	 inhibition	 (Brasca,	
Albanese	et	al.	2010).	
AT7519	is	a	general	CDK	inhibitor	developed	by	Astexs	pharmaceuticals	(Cambridge,	
UK).	 	 This	 compound	was	 developed	 using	 fragment-based	 X-ray	 crystallographic	
screening.	 	 Fragments	 are	 low-molecular	 weight	 compounds	 with	 low	 binding	
affinities	 and	 screening	 using	 X-ray	 crystallography	 yields	 small	 libraries	 of	








of	 cancer	 cell	 lines	 confirmed	 the	 antiproliferative	 activity	 of	 AT7519	 and	 TUNEL	
staining	 assays	 and	 colony	 formation	 confirmed	 induction	 of	 apoptosis	 in	 colonic	
and	ovarian	cancer	cell	 lines,	 interestingly	an	exposure	equivalent	or	greater	 than	
one	 cell	 cycle	 was	 required	 for	 induction	 of	 apoptosis	 suggesting	 that	 AT7519	
needed	 to	 be	 present	 during	 certain	 points	 in	 the	 cell	 cycle.	 	 In	 this	 initial	
investigation	a	xenograft	model	using	HCT116	(a	colonic	cancer	cell	line)	was	carried	
out	 that	 showed	 delayed	 tumour	 growth	 and	 tumour	 regression	 in	 an	 advanced	
cancer	 model	 compared	 to	 controls	 (p<0.05).	 	 CDK2	 substrates	 were	 also	 tested	
from	this	xenograft	model,	namely	 the	phosphorylation	of	NPM	and	Rb	and	were	
shown	to	decrease	after	certain	time	points	post	dose.	
The	 key	 to	 the	 future	 of	 chemotherapy	 in	 pancreatic	 cancer	 will	 be	 the	





and	 in	 a	 pancreatic	 cancer	 xenograft	 model	 as	 a	 potential	 novel	 therapy	 to	 be	
remained sensitive to AT7519. Because functional Rb is
required for CDK4 inhibition to result in cell cycle arrest
(reviewed in ref. 32), this suggests that the anti-CDK4
activity of AT7519 alone is not responsible for the
antiproliferative effects. In contrast to the compound’s
potent activity against cycling tumor cell lines, AT7519 did
not affect the viability of noncycling MRC-5 cells at
concentrations up to 10 Amol/L. These data suggest that
the mechanism by which the compound exerts its effect is
cell cycle related and the compound is not generally
cytotoxic to cells that are not dividing.
The mechanism of action of AT7519 in cells has been
investigated by monitoring the phosphorylation state of
substrates specific for the various CDKs within treated
HCT116 cells (Fig. 1B). These studies indicated that
inhibition of cellular CDK1 and CDK2 by AT7519 was
observed at concentrations consistent with the observed
antiproliferative effects. Treatment with AT7519 for 24 h
was sufficient to inhibit phosphorylation of the CDK1
substrate PP1a (T320) and the CDK2 substrates Rb (T821)
and NPM (T199) in HCT116 cells. Additional studies
showed phosphorylation of NPM and Rb to be inhibited
following a 1 h exposure to AT7519 (data not shown),
suggesting that these inhibitory effects on substrate
phosphorylation were a direct effect of CDK inhibition
rather than a consequence of cell cycle arrest. No effect of
AT7519 was observed on the cyclin D-dependent phos-
phorylation site on Rb (S780) in cell-based systems despite
the observation in cell-free kinase assays that the com-
pound inhibited CDK4/cyclin D activity (Supplementary
Table S1).1 This supports the previous observation in Rb-
negative cells (MDA-MB 468) that inhibition of CDK4 by
AT7519 was not responsible for its antiproliferative effects.
Levels of the relevant cyclins, CDKs, and total proteins
remained unaffected by compound treatment. The effects
of the compound on phosphorylation of the COOH-
terminal domain repeats of RNA polymerase II were also
assessed. AT7519 inhibited phosphorylation of RNA
polymerase II on Ser2 of the COOH-terminal domain,
indicating that AT7519 has the potential to inhibit
transcription downstream of the polymerase, consistent
with the observed in vitro inhibition of CDK9. Inhibition of
total transcription was assayed using tritiated uridine
incorporation into RNA and showed that a 4 h treatment
of HCT116 cells with AT7519 was sufficient to inhibit
global transcription with an IC50 of 56 nmol/L (data not
shown), similar to the levels required for inhibition of
proliferation (Table 1).
AT7519 Inhibits Cell Cycle Progression in Human
Tumor Cell Lines
The effect of AT7519 on cell cycle progression was
investigated in HCT116 cells. Cells treated for 24 h with
increasing concentrations of AT7519 showed a significant
reduction in the number of cells in S phase and an increase
in the number of cells in G2-M (Fig. 2A). Colabeling with
bromodeoxyuridine and propidium iodide showed that
cells were also arrested in the G0-G1 phase of the cell cycle
(data not shown). An increase in cells containing sub-G1
Figure 1. Chemical structure of AT7519 (A). HCT116 cells were treated for 24 h with AT7519 and lysates were prepared for Western blotting.
Representative of three independent experiments (B).
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Pancreatic	 cancer	 cell	 lines	 SUIT-2,	 Miapaca-2,	 CFpac,	 Fampac	 and	 paca2	 were	
derived	from	stores	 in	the	department	of	Clinical	and	Molecular	Cancer	Medicine,	
University	 of	 Liverpool.	 	 Panc-1	 was	 supplied	 by	 LGC	 standards	 from	 the	 ATCC.		
SUIT-2	 (GR)	 (a	 gemcitabine	 resistant	 pancreatic	 cancer	 cell	 line	 derived	 from	 the	
parent	 line	 SUIT-2	 was	 developed	 in	 the	 department	 of	 molecular	 and	 clinical	
cancer	medicine	 by	 K	 Dejani.	 Cells	 were	 grown	 in	 RPMI	 supplemented	with	 10%	
foetal	 bovine	 serum	 and	 maintained	 at	 37oC	 in	 an	 atmosphere	 of	 5%	 CO2.	
Pancreatic	cell	lines	were	cultured	as	previously	described.		
AT7519	 is	 N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)	 1H-pyrazole-3-
carboxamide.	 AT7519	 was	 obtained	 from	 Astex	 Pharmaceuticals	 Ltd	 (Cambridge,	
UK).	 It	was	dissolved	first	 in	dimethyl	sulfoxide	(DMSO;	Sigma	Chemical,	USA)	at	a	
concentration	 of	 10	 mM,	 and	 then	 in	 culture	 medium	 immediately	 before	 use.	




AT7519’s	 effects	on	 viability	of	 PDAC	 cell	 lines	 and	 isobolar	 analysis	 of	AT7519	 in	
combination	with	gemcitabine	was	assessed	using	the	cell	proliferation	assay	EZ4U	






An	 assessment	 of	 synergy	 (or	 antagonism)	 was	 carried	 out	 using	 isobolographic	
analysis	(berenbaum	1989,	tallarida	1989	1992).		Cells	were	plated	and	cultured	as	





display	 the	 relationship	 between	 the	 agents	 in	 combination	by	 plotting	 a	 straight	
line	 connecting	 the	 two	 agents	 IC50	 points	 representing	 an	 additive	 effect.	 	 	 The	






Cell	 cycle	 analysis	 was	 performed	 using	 propidium	 iodide	 (PI)	 staining	 and	 flow	
cytometry.	Miapaca-2	cells	were	seeded	onto	6	well	plates	at	2.5	x	105	cells	 	per		
well,			grown	overnight			and	then	treated	with	AT7519,	gemcitabine	(+/-)	or	control	
(0.1%	DMSO	or	PBS)	 for	 various	 time	points	 	 at	doses	 	detailed	 in	 figure	 legends.		
Both	 adherent	 and	 floating	 cells	were	 collected	 and	washed	with	 twice	with	 PBS	
prior	 to	 fixation	 in	 70%	 ethanol	 overnight	 before	 staining	 with	 PI	 (50ug/ml)	 for	







To	 determine	 the	 timing	 and	 mechanism	 of	 cell	 death	 caspase	 3/7	 activity	 was	
assessed	using	 the	Caspase-Glo	3/7	 luminescent	assay	 (promega).	Miapaca-2	cells	








Pancreatic	 cancer	 cells	 were	 cultured	 with	 AT7519	 a	 variable	 concentrations,	
harvested,	 washed	 and	 lysed	 using	 lysis	 buffer	 as	 previously	 described	 by	 Astexs	
pharmaceuticals	 (ref).	 The	 protein	 concentration	 of	 lysate	 was	 measured,	 mixed	




at	 37oC.	 Immunoblotting	 was	 done	 with	 cdc2,	 Rb,	 pRb	 from	 Cell	 signalling	
Technology.	Decetction	was	performed	using	ECL	reagents.		Blots	were	stripped	and	




To	 evaluate	 the	 in	 vivo	 tolerability	 and	 efficacy	 of	 AT7519,	 gemcitabine	 and	




BD	 5	 days	 per	week,	 gemcitabine	 50	 or	 75mg/kg	 2qw	 or	 AT7519	 7.5mg/kg	 BD	 5	
days	per	week	+	gemcitabine	50mg/kg	2qw.		Body	weights	and	general	observations	
were	performed	daily,	experimental	endpoints	were	a	 loss	of	>20%	of	day	1	body	
weight	 in	 two	or	more	 animals	 (sustained	over	 a	 72	 hr	 period)	 or	 death	of	more	
than	one	 animal.	 	 Animals	were	not	 dosed	 if	 their	was	 a	 >15%	body	weight	 loss.		
Necropsy	 for	 serum	 and	 organs	 was	 performed.	 	 For	 Efficacy	 studies	 mice	 were	
inoculated	with	Miapaca-2	pancreatic	cancer	cells.		Miapaca-2	were	supplied	by	LGC	
standards	from	the	ATCC	that	had	been	cultured	and	frozen	in	stocks	adequate	for	
all	 in	 vivo	 studies	 then	defrosted	 and	 cultured	 in	 T75	 flasks	 until	 90%	 confluence	






measured	 every	 alternate	 days	 in	 three	 dimensions	 using	 callipers,	 and	 tumour	










a	 representative	 experiment	 was	 selected	 for	 Figures.	 Statistical	 significance	 of	
differences	 for	 both	 in	 vitro	 and	 in	 vivo	 experiments	 were	 determined	 using	
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shown).	 	 	 The	gemcitabine	 resistant	 cell	 line	 Suit-2	GR	had	was	 found	 to	have	an	
IC50	of	 625nM	 to	 gemcitabine	 compared	 to	 10nM	 in	 the	 parent	 line	 Suit-2.	 	 The	
AT7519	 IC50	 was	 lower	 in	 the	 gemcitabine	 resistant	 cell	 line	 	 (700nM)	 than	 the	






































Cell	 cycle	 analysis	 was	 performed	 on	 suit-2	 cells	 cultured	 with	 media	 alone	 or	
AT7519	 (10uM)	 for	 4,	 7,	 24	 and	 48	 hours.	 	 Following	 24	 hours	 treatment	 with	
AT7519	there	was	clear	arrest	in	G2/M	phase	with	a	reduction	in	the	proportion	of	
cells	in	G0/G1	and	S	phase	compared	to	untreated	cells	(p=<0.001).		When	AT7519	







[a]Cell	 cycle	 distribution	 of	 SUIT-2	 pancreatic	 cancer	 cell	 line	 untreated	 (media	
only),	treated	with	AT7519	(nm),	treated	with	AT7519	(nm)	and	gemcitabine	(nM)	
at	4,	7,	24	and	48	hours.	




Apoptosis	was	demonstrated	after	 treatment	with	AT7519	 in	 vitro	by	 caspase-3	
activity	(figure	3)	
Evidence	of	induction	of	apoptosis	by	AT7519	in	pancreatic	cancer	cell	lines	tested	
was	 limited.	 	 Caspase-3	 activity	 was	 investigated	 and	 at	 24	 hours	 induction	 of	
caspase-3	 was	 significantly	 increased	 in	 treated	 cells	 compared	 to	 untreated	
control.		
	
Figure	 3.	 caspase-3	 activity	 of	 untreated	 and	 AT7519	 treated	 Miapaca-2	
pancreatic	cancer	cells		at	6,	16,	24,	40,	48	and	72	hours.	
	
Isobolar	 analysis	 of	 AT7519	 combined	 with	 gemcitabine	 suggested	 an	 additive	
effect	(figure	4)	
Initial	 experiments	 performed	 demonstrated	 an	 antagonistic	 effect	 when	 AT7519	
and	gemcitabine	was	given	simultaneously	(data	not	shown)	consistent	with	a	need	
for	cells	 to	be	dividing	 in	order	 for	gemcitabine	 to	have	an	effect.	 	 In	 light	of	 this	
experiments	 were	 performed	 giving	 gemcitabine	 alone	 for	 the	 first	 24	 hrs	 of	
incubation	followed	by	the	addition	of	AT7519.	 	These	experiments	demonstrated	


































blot	analysis	 confirmed	decreased	CDK1	 levels	 further	 supporting	 the	G2/M	block	
effect	 of	 AT7519	 not	 observed	 with	 gemcitabine	 as	 a	 single	 agent.	 	 When	
gemcitabine	and	AT7519	were	used	in	combination	this	decrease	in	CDK1	was	not	
observed	 supporting	 the	 notion	 that	 cells	 need	 to	 be	 dividing	 in	 order	 for	 G2/M	
block	to	occur.		This	was	confirmed	by	sequential	addition	of	gemcitabine	alone	for	
24	 hours	 followed	 by	 AT7519,	 this	 lead	 to	 appropriate	 variation	 of	 CDK1.		
Phosphorylation	 of	 Rb	 is	 catalysed	 by	 cyclin-dependant	 kinases	 and	 inhibited	 by	



































[b]Combination:	 25nM	Gemcitabine	 and	 desired	 concentration	 of	 AT7519	 added	
together	
Sequential:	 Cells	 treated	 with	 25nM	 of	 Gemcitabine	 for	 24h	 followed	 by	 the	
addition	of	the	desired	concentration	of	AT7519	
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cdc2 Β actin 34kDA 
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Combis: 25nM Gemcitabine and desired concentration of AT7519 added together 
Sequential: Cells treated with 25nM of Gemcitabine for 24h followed by the addition of the 


























days	 and	 in	 combination	 studies.	 	One	 animal	 died	 due	 to	 an	 injury	 unrelated	 to	

























































In	 a	 xenograft	 model	 of	 pancreatic	 cancer,	 AT7519	 as	 a	 single	 agent	 and	 in	
combination	with	gemcitabine		showed	a	significant	reduction	in	tumour	growth	
compared	to	vehicle	control	(figure	7)	
SUIT-2	 pancreatic	 cancer	 cell	 line	 were	 successfully	 cultured	 and	 developed	
subcutaneous	 solid	 tumours	 in	 nude	 mice	 with	 matrigel.	 	 Tumours	 grew	 in	 an	
exponential	 fashion.	 	 From	 tolerability	 studies	 animals	 were	 dosed	 appropriately	
with	AT7519,	gemcitabine,	vehicle	control	(saline)	or	a	combination	of	AT7519	and	
gemcitabine.	 	 During	 the	 single	 agent	 efficacy	 study	AT7519	 significantly	 reduced	
the	 exponential	 tumour	 growth	 (p=0.043)	 as	 did	 gemcitabine	 (p=0.0038).	 	 There	
was	 no	 significant	 body	weight	 loss	 in	 the	 single	 agent	 dosing	 of	AT7519.	 	 In	 the	
combination	efficacy	study	of	AT7519	and	gemcitabine	a	further	beneficial	effect	of	













Vehicle	control	 0.162	 6	 0.502	
AT7519	 0.29	 6	 0.045	









































































































































































Vehicle	 0.05	 6	 -	 0.9991	 0.9906	
Gemcitabine	 0.162	 6	 0.0198	 -	 0.1477	
AT7519	 0.114	 6	 0.029	 0.9374	 -	
AT7519	+	
Gemcitabine	
0.249	 6	 0.0041	 0.0611	 0.0173	
	








activity	 has	 been	 documented	 as	 one	 of	 the	 hallmarks	 of	 cancer	 (Hanahan	 and	
Weinberg	 2011).	 	 The	 investigation	 of	 CDK	 inhibition	 and	 small	 molecule	 novel	
agents	 such	as	AT7519	 is	 appropriate	and	may	 improve	 survival	 in	PDAC(Lapenna	
and	Giordano	2009).	The	relative	chemoresistance	of	pancreatic	adenocarcinoma	to	
standard	 therapy	 remains	 a	 current	 problem	 and	 at	 least	 partly	 explains	 the	
relatively	poor	survival	associated	with	PDAC	both	in	the	resectable	and	advanced	
setting.	 	 With	 greater	 understanding	 of	 cancer	 biology	 and	 the	 need	 for	 new	
approaches	novel	 therapies	 remain	an	 important	avenue	 to	attempt	 to	overcome	
these	issues.		AT7519	a	novel	CDK	inhibitor	investigated	here	shows	efficacy	in	vitro	
against	 a	 range	 of	 pancreatic	 cancer	 cell	 lines	 and	 activity	 against	 a	 gemcitabine	
resistant	cell	line.		In	cell	cycle	analysis	AT7519	showed	activity	in	line	with	expected	
CDK	inhibition	as	for	mentioned	an	important	pathway	in	cancer	biology	and	its	cell	
cycle	 effects	 in	 combination	 with	 gemcitabine	 offers	 important	 information	




activity.	 	 	When	downstream	markers	were	 investigated	 the	effects	of	AT7519	on	
key	pathways	in	the	cell	cycle	was	demonstrated	and	again	the	importance	of	dose	
scheduling	highlighted.		The	importance	of	scheduling	AT7519	with	gemcitabine	to	
allow	 both	 agents	 to	 take	 maximal	 effect	 was	 further	 demonstrated	 by	 isobar	
analysis	supporting	the	principle	that	gemcitabine	needs	cells	to	be	diving	in	order	
to	 have	 an	 effect.	 	 In	 a	 murine	 model	 AT7519	 was	 well	 tolerated	 and	 showed	
efficacy	 both	 as	 a	 single	 agent	 and	 in	 combination	with	 gemcitabine	 significantly	
reducing	tumour	burden.		
In	 targeting	 multiple	 pathways	 general	 CDK	 inhibitors	 such	 as	 AT7519	 provide	 a	
promising	 therapeutic	 option	 excerpting	 both	 direct	 cell	 cycle	 and	 transcription	
effects(Malumbres	 2012),	 evidence	 of	 actions	 on	 some	 of	 these	 known	 aberrant	
pathways	have	already	been	investigated.		Fry	et	al	demonstrated	the	activity	of	PD	
000332991	on	tumour	xenografts,	this	CDK	inhibitor	specifically	targets	CDK4	and	6	
and	 therefore	 the	 downstream	 phosphorylation	 of	 Rb(Fry,	 Harvey	 et	 al.	 2004).		
More	 recently	 a	 novel	 CDK	 inhibitor	 Dinaciclib	 was	 demonstrated	 to	 inhibit	
pancreatic	 cancer	 progression	 in	 a	 murine	 model	 and	 its	 CDK5	 inhibition	
hypothesised	to	affect	Ras-mediated	Ral	activation(Feldmann,	Mishra	et	al.	2011).		
Regarding	 the	 use	 of	 CDK	 inhibitors	 in	 pancreatic	 cancer	 the	 important	 question	
remains	that	which	CDKs	or	range	of	CDKs	should	be	target	and	would	provide	the	
optimum	therapeutic	option	for	this	disease.		As	the	knowledge	on	the	genetic	basis	















The	 key	 to	 the	 future	 of	 adjuvant	 therapy	 in	 pancreatic	 cancer	 will	 be	 the	
identification	 of	 novel	 and	 effective	 agents,	 better	 biomarker	 technology	
underpinned	by	 translational	 research	 that	will	 inform	 the	design	 of	 future	 trials.	
AT7519	 inhibited	 growth	 in	 pancreatic	 cancer	 cell	 lines	 including	 one	 that	 has	
acquired	gemcitabine	resistance	and	was	effective	in	combination	with	gemcitabine	
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